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ABSTRACT 
 
To treat obesity, one approach is developing food products formulated to trigger 
the ileal brake, a gastric feedback mechanism that induces satiety, the prolonged feeling 
of fullness.  PYY and GLP-1, biomarkers of the ileal brake, are secreted from the ileum 
upon macronutrient exposure.  Circulating PYY and GLP-1 bind to receptors in the 
hypothalamus, suppressing appetite and food intake.  In three research phases, the 
hypothesis that two orally consumed emulsions, composed of palm and fish oil, induce 
satiety and reduce energy intake, was tested. 
In phase one, it was hypothesized that the emulsions promoted the secretion of 
PYY and GLP-1 from the murine intestinal cell line, STC-1.  The STC-1 cells were 
treated with each emulsion and the hormone response was assayed.  The results 
demonstrated that the emulsions promoted PYY and GLP-1 secretion from the STC-1 
cultures.  These findings suggest that the emulsions may have potential as satiety 
inducing agents in human volunteers.   
In phase two, it was hypothesized that a formulated fruit and dairy smoothie-type 
beverage could serve as vehicle for the satiety inducing emulsions.  Beverages with or 
without the emulsions constituted the treatments.  To test this hypothesis, subjective and 
objective analyses were performed.  Subjective analyses using human volunteers 
compared sensory aspects of each treatment.  Objective analyses using appropriate 
instrumentation compared the viscosities, pH and color of each treatment.  There were 
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no statistically significant differences in the subjective and objective results, confirming 
that the beverage is a suitable emulsion vehicle. 
Phase three tested the hypothesis that the treatments induced satiety, reduced 
energy intake and induced a satiety hormone response in human subjects.  10 subjects 
consumed three treatments in a crossover study in which self-reported satiety, food 
intake, and satiety hormones were investigated.  Blood sample analyses and completed 
satiety questionnaires were used to assess treatment effects over a 180 minute interval.  
Following the 180 minute interval, subjects consumed a satiety meal to achieve satiation, 
at which point food intake was measured.  Consumption of each treatment did not 
demonstrate significant differences for any subject-reported satiety, biomarker analysis 
and food intake.   
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NOMENCLATURE 
 
GLP-1 Glucagon-like-peptide 1 
PYY Peptide YY 
CCK Cholecystokinin 
GI Gastrointestinal  
TAG Triacylglycerol 
FFA Free fatty acid 
MCT Medium chain triacylglycerol 
LCT Long chain triacylglycerol 
DPP-4 Dipeptidyl Peptidase-4 
POMC Proopiomelanocortin 
MSH Melanocyte-stimulating hormone 
NPY NeuropeptideY 
AgRP Agouti-related peptide 
CNS Central nervous system 
ESNL Exercise and Sports Nutrition Laboratory 
SSS Sensory specific satiety 
OCCT Orocecal transit time 
DATEM Diacetyl tartaric acid ester of mono-diglycerides 
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CHAPTER I  
INTRODUCTION 
 
RESEARCH GOALS 
Overall Goal 
The goal of this research project was to test the hypothesis that two orally 
consumed emulsions, composed of varying ratios of palm and fish oil, influenced satiety, 
the prolonged feeling of fullness and satiation following meal consumption.  
Specifically, it was hypothesized that the emulsions promoted satiety by triggering the 
ileal brake, a gastric feedback mechanism that promotes appetite suppression by 
delaying gastric emptying and inhibiting intestinal motility.  This research project 
consisted of three phases briefly described below.  
 
Phase One –The Effects of Emulsions on Satiety Hormone Secretion in Cell Culture 
The goal for phase one was to determine if the two emulsions stimulated the 
secretion of the ileal brake biomarkers, PYY and GLP-1 from the murine intestinal cell 
line, STC-1.  STC-1 cells secretes PYY and GLP-1 upon nutrient stimulation in a 
manner similar to human endocrine intestinal cells.  The STC-1 cell cultures were 
treated with the two emulsions and their effects on the secretion of PYY and GLP-1 
were assayed.  The results of phase one determined if there was potential for the two 
emulsions to trigger the ileal brake when consumed by individuals. 
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Phase Two – Analysis of a Beverage Formulated With Satiety Inducing Emulsions 
The goal of phase two was to formulate a fruit and dairy beverage to serve as a 
vehicle for the emulsions in human volunteers.  For clarity, the beverage, when 
combined with either of the emulsions or control, was referred to as a treatment.  For 
each treatment, subjective sensory tests and objective instrumental analysis were 
performed to ensure that there were no objective or subjective differences among 
treatments.  For the subjective sensory tests, triangle tests and acceptance/affective tests 
were administered on individuals.  The objective tests employed laboratory 
instrumentation to analyze and compare the viscosities, pH and Hunter L, a, b color 
values of each treatment.  Any measurable differences between treatments could 
influence satiety measurements and food intake in human volunteers.    
 
Phase Three – Effects of Each Treatment on Satiety in Human Subjects 
 In phase three, we investigated whether the three treatments formulated in phase 
two induced satiety, reduced food intake, and upregulated the expression of the 
satiety/hunger biomarkers, GLP-1, PYY, ghrelin and leptin in human volunteers to infer 
activation of the ileal brake.  Ten subjects were recruited in a randomized, single-blind 
placebo-controlled, crossover study design.  Each subject consumed each treatment 
separated by one week intervals.  Over the 180 minute period post-treatment 
consumption, subjects reported satiety by completing VAS questionnaires.  During that 
same timeframe, blood samples were collected and later assayed for ghrelin, leptin, PYY 
and GLP-1.  To determine if the treatments reduced food intake, all subjects were 
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provided a cheese pizza lunch following the 180 minute timeframe.  Subjects were 
instructed to consume pizza until sufficiently satiated.  All of the aforementioned tests 
were necessary to determine if the treatments affected satiety, energy intake and 
hormone expression as a means to control appetite and counter obesity. 
 
BACKGROUND 
Health Concerns Relating to Obesity 
Obesity has emerged as a serious threat to the world health population and has 
continued on an upward trend since the mid-1980s.  Obesity is defined as abnormal or 
excessive fat accumulation in individuals that may impair health.  It is caused by a 
caloric surplus resulting from excessive food consumption combined with a lack of 
sufficient physical activity.  Overweight and obese individuals are risk factors for 
chronic diseases such as diabetes, cardiovascular diseases and cancer.   
Body mass index (BMI) is the most common measurement of obesity, which is 
calculated by dividing the individual’s weight (in kilograms) by the square of their 
height (in meters).  Table 1 displays the BMI classification chart.   
 
BMI range 
(kg/m2) 
Classification 
Less than 18.5 underweight 
18.5 - 25 normal weight 
25.1 – 29.9 overweight 
Greater than 30 obese 
Table 1 - BMI Classification Chart 
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As of August 2014, the World Health Organization recently reported the 
following: worldwide obesity has nearly doubled since 1980; in 2008, more than 1.4 
billion adults, 20 and older, were overweight, of which over 200 million men and nearly 
300 million women were obese; 35% of adults aged 20 and over were overweight in 
2008, and 11% were obese; 65% of the world's population live in countries where 
overweight and obesity kills more people than underweight; more than 40 million 
children under the age of 5 were overweight or obese in 2012 [1].   
The World Health Organization recommends the following dietary guidelines to 
treat obesity: limit total fat intake, shift fat consumption away from saturated fats to 
unsaturated fats, eliminate foods high in trans-fatty acids, increase the consumption of 
fruits, legumes, whole grains, nuts and vegetables, limit the intake of free sugars, and 
limit sodium consumption [1].  In the USA, dietary guidelines are established jointly by 
the United States Department of Agriculture and the United States Department of Health 
and Human Services.  Food product formulations are developed following those 
guidelines.  
 
Inflammatory Response in Obese Individuals 
 In addition to adding excessive amounts of body fat, obesity also disrupts the 
normal metabolic process.  One such disruption is the activation of immune response 
pathways leading to inflammation.  For disease-free humans of normal BMI, 
inflammation represents an immune system response to a site of injury or infection.  The 
response often leads to signs of redness, swelling, heat or pain.  However, in obese 
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individuals, as well as individuals suffering from Type 2 diabetes, the inflammatory 
response is strictly metabolic and caused by excessive nutrient consumption.  It is 
characterized by abnormal cytokine production, and activation of a network of 
inflammatory signaling pathways in metabolic cells such as adipocytes [2, 3].   The 
exact methods that lead to stimulation however are unknown, but under normal 
conditions, nutrients will stimulate metabolic pathways, leaving the pathogen-sensing 
and immune response pathways inactive.  In conditions of excess nutrient intake, the 
nutrients can overload the metabolic pathways stimulating the pathogen-sensing 
pathways and then after prolonged exposure can activate the immune response 
pathways.  The latter pathways can prevent the drain of nutrient metabolism causing a 
backlog of nutrients in the system, blocking anabolic activity (Figure 1).   Therefore 
anti-inflammatory ingredients/drugs are necessary to promote normal cell metabolism. 
 
 
Figure 1 - Prolonged Overconsumption of Nutrients Leads to Immune Response 
This figure illustrates how excessive nutrients affect the immune response in individuals.  Adapted from Ref. [4] 
 
 
Healthy Nutrient Intake Excess Nutrient Intake Prolonged Excess Nutrient Intake
Metabolic
Pathways
Pathogen-
sensing
Pathways
Immune-
response
Pathways
Nutrient
input
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Satiety, Hunger and Appetite in Obesity 
Satiety, hunger, and appetite, directly or indirectly, are involved in energy 
balance and therefore are important consideration when considering obesity.  Hunger is 
defined as the physiological need for food and is affected by factors such as an empty 
stomach, a decrease in blood glucose levels, and alterations in circulating hormones.  
Appetite is the psychological desire to eat, and is associated with the sensory aspects of 
food such as sight and smell.  Hunger and appetite are not always mutually inclusive.  
During times of sickness individuals can experience hunger but not appetite.  
Conversely, the desire to eat a desert after consuming a nutritious meal influences 
appetite but not hunger.  The latter instance plays a significant role in the development 
of obesity [5].   
Satiation is the feeling of fullness that occurs during the onset of eating, while 
satiety is the physiological and psychological feelings of fullness and satiation that 
comes post meal.  Individuals who are overweight or obese typically consume greater 
quantities of food to experience the necessary feelings of fullness and satiation after 
eating, leading to a surplus of stored energy [5].   
Energy restriction is most commonly employed to counter obesity, but a more 
effective long term solution may lie in the manipulation of macronutrient composition of 
diets to fortify foods or beverages with macromolecules that can trigger the release of 
the hormones that regulate hunger, food intake and satiety to promote weight 
maintenance  (Figure 2) [6].   
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Figure 2 - Potential Effect of Satiety Inducing Beverage on Energy Intake 
Shows how beverages supplemented with macromolecules that enhance feelings of satiety can potentially influence 
energy intake.   
 
 
Psychological Factors Affecting Satiety 
 As will be discussed in greater detail in an upcoming section, the human body 
possesses physiological mechanisms to control appetite.  However, it is important to take 
into account not only such mechanisms but also external factors that may influence 
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appetite or satiety.  The factors that will be briefly discussed are palatability, variety, 
portion size, television viewing and social situations.   
 Palatability refers to the pleasurable experiences resulting from food 
consumption.  Palatability of food may be altered by adding fat, sugar, protein, texture 
agents and color agents, etc.  Typically, increasing the palpability by any of the 
aforementioned methods often leads to an increase in appetite, meal size, meal duration 
and eating rate [7, 8].   Several studies demonstrated that satiation and palatability have 
an inverse relationship, meaning that the most palatable energy dense foods tend to be 
least satiating while the least palatable foods tend to be most satiating [8-10].   De Graaf 
et al. argued that increasing palatability potentially affects satiation but not satiety [11].  
While palatable energy dense foods have been demonstrated to reduce satiety, it was 
suggested that formulating less energy dense foods, that are both healthy and satiating 
should be a research focus [12].   
 Variety of food being offered also affects individual food consumption and 
satiety.  It has been shown that offering a greater the variety of food, often leads to 
greater food consumption, partially due to a phenomenon known as sensory specific 
satiety (SSS).  SSS refers to the individual desire to consume one food item that has 
already been consumed is reduced compared to another food item that has not been 
consumed [13].  Offering a wide of variety of foods seemingly minimizes the effect of 
SSS leading to higher overall food consumption and that restricting the variety of foods 
promotes satiety [13].   
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 In the USA, portion sizes of foods (i.e. hamburger patties, fried foods) have 
increased over the past four decades, while portion sizes have remained relatively 
constant in Europe.  The effect portion size has on satiety vary.  Several studies found 
that satiety increased with larger portion sizes, while other studies found no differences 
in appetite ratings between larger and smaller portions sizes despite a significant 
increase in energy intake when consuming the larger portion size [14-19].  Generally, 
larger portion size appears to increase energy intake since consumption of a larger 
portion size is rarely followed by a subsequent energy reduction [7].     
 Television viewing has the potential to increase energy intake and food 
consumption in that it potentially desensitizes individuals to internal signals of satiation 
and satiety [20].  It has been suggested that television increases motivation to eat and 
that the attention needed to watch a continuous television programming is a distraction 
to an individual’s normal eating patterns [21].  Television viewing increases sedentary 
time and increases opportunities to eat, promoting weight gain [22].  
Peer influence in social settings potentially affects satiety since individuals have 
a tendency to consume greater food quantities in the presence of others than when alone 
[23].  Two studies demonstrated that individuals consumed greater food quantities in the 
presence of others in a social setting due to prolonged meal length, resulting in increased 
energy intake [24, 25].  Therefore, peer influence in social settings should also be taken 
into consideration as a factor affecting satiety.   
 In summary, palatability, variety, portion size, television viewing, and social 
interactions all have an effect on appetite and satiety and also highlight the inherit 
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problems in extrapolating the results of a satiety study performed in a clinic where all 
confounding variables are minimized and controlled. 
 
Satiety and its Role in Energy Homeostasis 
As previously stated, satiety is the physiological and psychological experience of 
fullness that comes post meal consumption.  Satiety, however, is a much more complex 
process than such a definition would indicate.  From a biological standpoint, satiety is 
very tightly regulated by various organ systems including the nervous, endocrine and 
digestive systems and they all must properly coordinate to maintain energy homeostasis.   
 In the nervous system, pro-hunger and pro-satiety neurons, located in the 
hypothalamic arcuate nucleus of the brain stem, coordinate to maintain energy 
homeostasis.  The pro-hunger neurons are known as the neuropeptide Y/Agouti-related-
peptide (NPY/AgRP) neurons and the pro-satiety neurons are known as the pro-
opiomelanocortin/-melanocyte-stimulating-hormones (POMC/MSH) neurons.  Both 
of which are responsible for relaying hunger or satiety stimuli to the central nervous 
system (CNS).  See Figure 3. 
The NPY/ArGP expressing neurons, known as the hunger center, are responsible 
for producing the two pro-hunger peptides NPY and AgRP, which are expressed in 
response to energy needs.  Once expressed, NPY induces hunger as it binds to neurons 
located in the paraventricular nucleus, which will further relay hunger stimuli to the 
CNS.  AgRP is simultaneously expressed with NPY and exerts its effects by inhibiting 
the action of the POMC/MSH neurons [26-28].  It is worth mentioning that in mice, the 
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deletion of the NPY gene unexpectedly promoted obesity, suggesting a disruption in the 
complex regulation system of bodyweight [29]. 
 The POMC/MSH expressing neurons, known as the satiety center, produce 
melanocortins (MSH), which are cleaved from the POMC precursor molecule.  MSH 
exerts its effects upon binding to melanocortin receptors (MC4) located on neurons in 
the paraventricular nucleus that will further relay appetite suppressing stimuli to the 
CNS [30-32].  AgRP is released along with NPY and functions by preventing the 
binding of MSH to the MC3 and MC4 receptors [33].  Mutations in the MC4 receptors 
have been linked to obesity [34].   
Both the NPY/AgRP and POMC/MSH neurons require specific intercellular 
interactions and extracellular stimuli in the form of neurotransmitters or hormones to 
maintain energy homeostasis and regulate satiety and hunger (Figure 1).  The stomach, 
small intestine, pancreas, and adipose tissue all produce hormones that interact with both 
sets of neurons.   
The main hormones responsible for maintaining energy homeostasis are ghrelin, 
leptin, cholecystokinin (CCK), glucagon-like-peptide 1 (GLP-1), and Peptide YY 
(PYY).  The pro-hunger hormone ghrelin functions as an activator of the NPY/AgRP 
neurons.  The pro-satiety hormones leptin and GLP-1 function as activators of the 
POMC/MSH neurons.  Leptin and PYY3-36 function as inhibitors of NPY/AgRP 
neurons.  Refer to Figure 3 and Figure 4 for a diagram illustrating their functions.  The 
function of each of these hormones are briefly described in Table 2 and are elaborated on 
in further sections.  Having an understanding of the biological mechanisms and 
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hormones that affect satiety and an intestinal feedback mechanism known as the ileal 
brake play a significant role in development of food products to aid in the treatment of 
obesity [35]. 
 
 
Figure 3 - Diagram of Hormone Binding Sites in Hypothalamus 
Note: all solid lines indicate a neuronal stimulation effect, while dashed lines indicate a neuronal inhibitory effect.  
Ghrelin stimulates the Hunger Center to produce NPY and AgRP, while PYY3-36, Leptin and insulin inhibit NPY 
production.  Leptin, Insulin and GLP-1 activate the satiety center to produce MSH. NPY inhibits the satiety center 
and AgRP prevents MSH from binding to MC4 receptor. 
Adapted from Ref. [36]. 
 
 
 
CNS
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Figure 4 - Organ Sources of Hunger and Satiety Hormones 
All satiety hormones exert their effects by binding to specific receptors in the hypothalamus (Ghrelin, GLP-1, PYY 
and Leptin) or the vagal afferents along the gut (CCK).  Adapted from Ref. [37] 
 
 
 
Hormone Function Origin of Secretion Brief Description of Effects 
Ghrelin Hunger X/A-like cells of the stomach 
Secreted into circulation in response to hunger.  Will bind to 
ghrelin receptors in the brain to stimulate appetite. 
 
Leptin Satiety Adipose tissue 
Secreted from adipose tissue into circulation post meal 
consumption and will bind to leptin receptors in the 
hypothalamus to induce appetite suppression. 
 
GLP-1 Satiety 
L-cells of the ileal portion of 
the small intestine 
Secreted from L-cells into the bloodstream post meal 
consumption.  Will bind to receptors in the CNS and peripheral 
tissues to promote insulin secretion and inhibits glucagon 
release and delay gastric emptying.  Degraded by DPP-4 once in 
circulation. 
 
PYY Satiety 
L-cells of the ileal portion of 
the small intestine 
Secreted from L-cells into circulation post meal consumption in 
full length form.  It will be truncated by DPP-4 to the active 3-
36 form.  The 3-36 form binds to Y2 receptor to exert its effects 
on satiety. 
 
CCK Satiation 
I-cells of the duodenal portion 
of the small intestine 
Secreted by the I-cells into the bloodstream where it binds to 
CCK receptor and promotes the release of digestive enzymes 
and bile from the pancreas and gallbladder, and also delays 
gastric empyting. 
Table 2- Description of Satiety and Hunger Hormones 
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GLP-1 
 GLP-1 is one of several cleavage products of the proglucagon gene and is 
predominantly produced in the intestinal L-cells located along the mucosa of the ileum 
and the proximal colon (Figure 5) [38-41].  GLP-1 is an incretin that enhances glucose-
dependent insulin secretion, inhibits glucagon release from the pancreatic -cells and 
delays nutrient absorption through inhibition of gastric emptying and intestinal motility 
[42-44].  Due to the distribution of GLP-1 receptors in the CNS and peripheral tissues, 
GLP-1 exerts a wide range of effects [42-48].  GLP-1 exhibits rapid and prolonged 
effects in response to nutrient digestion post-meal consumption.  The rapid response of 
GLP-1 is stimulated by the vagus nerve by the release of acetylcholine which binds to 
M1 receptors on the L-cells promoting the secretion of GLP-1 [49-51].  Conversely, the 
prolonged response of GLP-1 secretion involves nutrients that traverse the 
gastrointestinal tract and directly interact with the L-cells upon binding to nutrient 
specific G-protein receptors such as GRP40, GRP43, GRP119, GRP120, FATP4 and 
TGR5 which activate a series of signal cascades leading to cleavage of proglucagon and 
the secretion of GLP-1 into circulation [52-64].  Once in circulation, GLP-1 has a half-
life of ~1-2 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) [65, 66].  
Once GLP-1 crosses the blood brain barrier, it will bind to receptors on the 
POMC/MSH neurons hypothalamic arcuate nuclei to promote appetite suppression. 
GLP-1 will also bind to receptors on the pancreatic -cells to promote synthesis and 
secretion of insulin [48, 67].  Lower circulating levels of GLP-1 have been reported in 
obese individuals, normal levels can reportedly be restored with weight loss, further 
 15 
 
elaborating on the role of GLP-1 in weight management and energy homeostasis [68, 
69].   
 
Figure 5 - Organ Specific Proglucagon Cleavage Products 
Adapted from Ref. [41] 
 
 
 
PYY 
PYY, like GLP-1, is a satiety hormone that is secreted by intestinal L-cells and 
serves as an inhibitor of pancreatic exocrine secretion and intestinal motility [70].   PYY 
contains a tyrosine (Y) residue at the amino and carboxylic acid terminus.  Unlike GLP-
1, the specific receptors and signaling cascades that lead to activation of PYY gene 
expression has not been fully elucidated in humans.  However in rats, it was reported 
that Insulin-like Growth Factor 1 functions as a positive regulator of PYY gene 
expression and that the stimulatory effect may be mediated by Sp1 proteins that bind to 
the proximal PYY promoter region [71].  Once in circulation PYY is degraded by DPP-4 
into its active PYY3-36 form.  PYY3-36 is able to exclusively bind to the Y2 receptor in 
the hypothalamic arcuate nucleus of NPY/AgRP-expressing neurons inhibiting the pro-
hunger effects of NPY.  DPP-4 mediated-cleavage of GLP-1 and PYY exert opposing 
effects on satiety.  This occurrence suggests a complex layer of satiety regulation and 
may explain why the DPP-4 inhibitor, vildagliptin does not alter satiation or gastric 
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volume in people with type 2 diabetes, despite elevated GLP-1 circulation [72].  It was 
previously shown that infusion of PYY3-36 into human subjects, results in a 30% or 
higher reduction in caloric consumption after two hours and a 33% reduction of food 
intake over 24 hours [73, 74].  Obese individuals have been reported to have lower levels 
of circulating PYY3-36 corresponding to reduced satiety [72-75].  It is important to note 
that in individuals who have undergone gastric bypass surgery, that circulating levels of 
PYY and GLP-1 are significantly increased and has been suggested to be a significant 
factor in weight loss post-surgery [76].   
 
Leptin 
Leptin, unlike CCK, GLP-1 and PYY, is not secreted from the intestines but 
mainly from white adipose tissue in response to food consumption.  Once in circulation, 
leptin crosses the blood brain barrier where it will bind to leptin receptors on both the 
POMC/MSH and NPY/AgRP neurons enhancing the action of the former and 
inhibiting the action of the latter.  Taken together, this pathway provides information to 
the brain regarding the amount of stored energy in adipose tissue in turn altering appetite 
and affecting energy expenditure [77].  Leptin circulations levels correlate closely with 
fat mass and decrease by as much as 50% after long periods of starvation [44, 77].  In 
obese mice that were leptin deficient, it was demonstrated that leptin administration 
reduced food intake and body mass [78].   However, leptin administration in obese 
humans failed produce similar results since the majority of obese individuals are leptin 
resistant [79].  Leptin resistance works in a method very similar to that of insulin in type 
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2 diabetes in that leptin is being produced but the appetite reducing effects are abrogated.  
The exact mechanism for leptin resistance is still under debate, but it has been proposed 
that accumulation of fat prevents leptins ability to cross the blood brain barrier and/or 
alterations in cellular leptin receptor signaling [80-82].  Leptin and/or leptin receptor 
mutations are linked to obesity due leading to excessive amounts of overeating, which 
can reversed by administration of leptin [83].  Leptin resistance and mutations is a 
significant factor in the development and treatment of obesity. 
 
Ghrelin 
Ghrelin is composed of 28 amino acids and is the only known appetite-
stimulating hormone.  It is produced in the P/D1 cells in the stomach [84].  Circulating 
ghrelin levels rise after overnight fasting and decreases post meal consumption in normal 
weight individuals.  In order for ghrelin to cross the blood barrier, the serine residue at 
position three must acylated by an octanoyl group.  Once ghrelin passes the blood-brain 
barrier, it binds to ghrelin receptor on the NPY/AgRP neurons promoting the production 
of NPY, stimulating appetite [85, 86].  Lower ghrelin levels are observed in obese 
individuals compared to lean individuals, while high ghrelin levels are associated with 
anorexia [87, 88].  In addition, the suppression of ghrelin that occurs post-meal in lean 
subjects is not observed in obese people and it has been suggested that due to excess fat 
storage ghrelin levels have already been maximally suppressed [89].  It’s worth nothing 
that dietary fat has been reported to suppress the release of ghrelin and therefore inhibit 
its pro-hunger effects [90].   
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CCK 
 CCK is considered a short-term, meal-reducing satiation hormone that is 
synthesized and secreted by the I-cells of the duodenum and was shown in rats and later 
in humans to suppress food intake [91-93].  Upon stimulation from nutrients, CCK is 
secreted into circulation and binds to receptors on several organs such as the gallbladder, 
pancreas and vagal afferents.  Binding to the gallbladder will induce the secretion of bile 
to aid in digestion [94].  CCK exerts its inhibitory effects upon binding to the CCK1 
receptor on vagal afferents which relays information to the hypothalamus leading to 
increased gastric distension induced by slowing gastric emptying which contributes to 
the satiation response [95-97].  While the satiation actions of peripheral CCK are well 
characterized, the role for brain CCK has been more controversial.  Given that CCK 
response occurs at the onset of meal consumption it is more appropriate to categorize 
CCK as a satiation hormone as opposed to a satiety hormone [7]. 
 
Serotonin 
 The role hormones play in satiety is well established and have become a target in 
obesity research and drug design, but the role of neurotransmitters, such as serotonin, 
play in satiety should not be ignored.  Serotonin is derived from tryptophan and 
produced from enterochromaffin cells that line the intestinal epithelium.  The conversion 
of tryptophan to serotonin is a two-step enzymatic process that involves hydroxylation at 
5’ position of the indole ring followed by decarboxylation of the alpha carbon.  Once 
released into circulation, serotonin will cross the blood brain barrier and bind to 5-HT1B 
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and 5-HT2C receptors located on the POMC/MSH neurons to promote serotonin-
induced satiety [98, 99].   Commercial drugs such as sibutramine, dexfenfluramine, 
fluoxetine and chlorophenylpiperazine are all known to be t5-HT2C receptor agonists, 
which have been used to treat obesity [100-103].  Findings indicate that consumption of 
tryptophan rich foods fails to increase serotonin production.  As such, formulated 
foods/diets rarely target serotonin-induced satiety, but instead target induction of the 
aforementioned satiety hormones.  [104].   
 
Effects of Macronutrients on Satiety 
 Most studies have focused on the effects proteins, fats and carbohydrates have on 
satiety.  Studies suggest that protein has the greatest effect on satiety compared to 
equivalent quantities of fat and carbohydrates.  Most short and long term studies 
measuring the effects of protein on satiety involved making a comparison between 
higher and lower protein preloads or diets monitoring satiety, energy intake and 
bodyweight change [7, 105].   A review of studies on protein, satiety and weight loss by 
Halton and Hu examined the results of many short-term and longer-term studies on 
satiety, energy intake and bodyweight change.  They reported that eleven out of fourteen 
studies demonstrated that a higher protein preload significantly increased ratings of 
satiety, and eight out of fifteen studies demonstrated that the subsequent energy intake 
was significantly reduced in the higher protein condition than in the lower preload 
control.  They concluded that substituting refined carbohydrates with protein sources 
that are low in saturated fat may be beneficial to promote weightloss [105].  Studies 
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which compared high to low protein preloads provided insight into the effect protein 
quantity provides on satiety and energy intake. However those studies did not provide 
insight into the role protein plays on satiety compared to fats and carbohydrates until 
Weigle et al. examined the effects of an isocaloric high protein diet compared to fat 
[106].  In the study, subjects were provided a diet that consisted of either low-protein 
(15% energy from protein, 35% from fat, 50% from carbohydrate) or high protein (30% 
energy from protein, 20% from fat, 50% from carbohydrate).   Subjects on the high 
protein diet reported higher feelings of satiety and a significant reduction of bodyweight 
based on being given ad libitum access to provided food after 12 weeks [106].  High 
protein diets are common when combined with very low amounts of carbohydrates.  
They are often known as ketogenic diets which saw a rise in popularity in the early-to-
mid 2000s  [107].  Such diets involve high fat, high protein and very low carbohydrate 
consumption to the push the body into a state of ketosis in which ketone bodies provide 
the main source of energy due to the lack of glucose from carbohydrates.  One study 
examined the effects of a high-protein low carbohydrate ketogenic diet (LCKD) (30% 
energy from protein, 4% from carbohydrates, 66% from fat) and high-protein medium 
carbohydrate non-ketogenic diet (MCND) on food intake and satiety.   Hunger and food 
intakes were found to be significantly lower for LCKD subjects compared to MCND 
subjects, while visual analogue scale (VAS) measurements of satiety were not found to 
be significantly different [108].   Evidence is consistent in that the energy from protein 
has a greater effect on satiety than equivalent energy amounts from fat or carbohydrates 
[7].   
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 Carbohydrates are very diverse in that they include, mono-, di-, and 
polysaccharides all made from simple sugars (mainly glucose).  The rate at which 
carbohydrates are digested is dependent on the chain length and the quantity of branch 
points.  Although, a short glucose polymer (commercially known as Vitargo) was shown 
to be absorbed at a quicker rate compared to glucose, its effects on satiety were not 
tested.  These findings suggest that other factors, in addition to chain length and branch 
point quantity, potentially affect digestion and absorption of carbohydrates [109].  
Sucrose and high fructose corn syrup are two of the most common sweeteners present in 
beverages. Their effects on satiety have been examined in multiple studies.  In all cases 
there was not a significant difference in satiety or energy intake between the two forms 
of sweeteners [110-112].  Much research focused on the effect the glycemic index has on 
satiety.  The glycemic index is a measure of the capacity of carbohydrate-containing 
foods to raise blood glucose compared with glucose.  Several studies examined the role 
and found that there was no significant difference in feelings of satiety comparing high- 
GI foods to low-GI foods [113-115].  Because of this it is very difficult to make 
definitive statements on the effect carbohydrates have on satiety. 
 The role fat plays in satiety is controversial and has been generally suggested that 
fat plays a less satiating role in satiety than proteins or carbohydrates [116, 117]. 
However, fat is significantly more energy dense (9 kilocalories per gram) than protein or 
carbohydrates (4 kilocalories per gram).  One study compared the effects of the addition 
of either a carbohydrate or fat supplement to a standard breakfast in lean male subjects 
on subsequent energy intake.  The carbohydrate supplement resulted in a short term 
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reduction in energy intake, while the fat supplement produced no reduction in 
subsequent energy intake [118].  Another study compared the effects of high protein 
(HP), high carbohydrate (HC) or high fat (HF) breakfasts on appetite ratings and energy 
intake.  They reported that the HP breakfast was most effective at suppressing appetite 
throughout the day, while the HF breakfast was least effective [119].  In the 
aforementioned studies factors such as chain length and degree of unsaturation were 
mostly not considered, but while it has been shown that chain length and degree of 
unsaturation may indeed influence feelings of satiety [120-122].   The form of fat and 
the method of delivery can have significant effects on satiety in activating a feedback 
mechanism known as the ileal brake, which will be discussed in the next section. 
 In summary, proteins, carbohydrates and fats all play a role in satiety/appetite 
and understanding the biological mechanisms in which they exert their effects is critical 
in the development of weightloss products designed to exploit these processes. 
 
Ileal Brake 
 The ileal brake is the primary inhibitory feedback mechanism that controls the 
transit of food through the GI tract (Figure 6).  Both GLP-1 and PYY serve as the most 
accepted biomarkers of the ileal brake.  The term was first described by Read et al. who 
demonstrated that a test meal transit time down the GI tract was delayed upon lipid 
emulsion perfusion into the distal portion of small intestine while Spiller et al. 
demonstrated that infusion of fat into the ileum reduces jejunal motility [123, 124].  Ileal 
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brake activation results in a delay in gastric emptying leading to an increase in small 
intestine transit time for both solid and liquid food [70, 125, 126].   
 
 
Figure 6 - The lleal Brake Mechanism 
Adapted from Ref.[127] 
 
 
 
Dietary fats predominantly in the TAG form that have been hydrolyzed into 
FFAs are considered the most potent activators of the ileal brake, as confirmed by many 
studies [70, 128-134].   Spiller et al. demonstrated that ileal infusion of FFA inhibited 
jejunal motility to a far greater degree compared to TAG and glycerol [129].  This was 
confirmed in several additional studies [135-137].  The possibility for FFAs having a 
more potent effect is due to the relatively low lipase activity in the ileum compared to 
the duodenum and jejunum.  In regards to fatty acid chain length, jejunal infusion studies 
demonstrated that FFAs with greater than ten carbons delay gastric emptying greater 
Feedback Inhibition of Gastric Emptying
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than FFAs of fewer than ten carbons [138, 139].  Ileal infusion of MCTs and LCTs were 
both shown to be activators of the ileal brake, which MCTs demonstrated a more rapid 
response [129].  The effect of degree of unsaturation of FFAs on ileal brake activation is 
still unclear, but some studies suggest that the satiating effects of unsaturated FFAs are 
greater than that of saturated FFAs [140-142].   
As previously discussed, many studies demonstrated that protein and 
carbohydrate consumption affect appetite and energy intake. However, the studies did 
not determine if those effects were the result of ileal brake activation.  A recent study 
investigated the effect of ileal infusion of sucrose and casein on food intake, release of 
CCK, GLP-1 and PYY, gastric emptying rate and small-bowel transit time.  They 
reported that the ileal brake-satiating effect leading to a decrease in food intake is also 
obtained from protein and carbohydrates [143].   This study however, was conducted 
using only normal weight individuals as a proof of concept study. 
Several earlier studies showed that carbohydrates, specifically maltose inhibit 
gastric emptying, reduce gastric acid secretion, decrease small intestine motility and 
decrease excretion of pancreatic enzymes which implies activation of the ileal brake, but 
those studies did not measure appetite or food intake [48, 144-146].   
It is important to note that most of the studies examining whether certain 
macronutrients could activate the ileal brake, were conducted via ileal infusion, which is 
not practical as a consumer weight management solution.  Ileal infusion of a 
macronutrient bypasses the extreme changes in pH and much of the mechanical and 
chemical digestion that orally consumed macronutrients would undergo.  Therefore, 
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activating the ileal brake using dietary means poses a much greater challenge.  As such, 
there is great interest in fortifying food products with macronutrients/ingredients that 
promote slow release of nutrients such that they can reach the ileum intact and activate 
the ileal brake.  Since lipids appear to be the most potent activator of the ileal brake, it is 
important to have a rudimentary understanding of lipid digestion. 
Brief Review of Lipid Digestion 
Fatty acids in the diet are provided in the form of triacylglycerols and 
phospholipids (especially from lean meats) and are obtained from a variety of sources 
such as animal meat, milk fat, but primarily from plant oils.  The stomach and intestines 
serve as the main organs responsible for the digestion of fats, but digestion actually 
begins in the mouth via the secretion of lingual lipases.   Even though lingual lipases are 
secreted from the serous glands of the tongue their optimum pH of operation is at 4.5 – 
5.5, which makes them most active in the stomach [147].  Once fat reaches the stomach 
further digestion continues via gastric lipase secreted from the gastric mucosa.  The 
churning of the stomach results in a physical reduction of fat particle size, which exposes 
the surface area for the lipases to act upon.  Gastric lipase cleaves at the sn-1 or sn-3 
position of the triacylglycerol backbone leading to sn-2,3-diacylglycerols or sn-1,2 
diacylglycerols and a free fatty acid.  The hydrolysis products of TAG help promote 
emulsion oil droplet formation.  
While about 10-30% of fat digestion occurs in the stomach, the bulk of fat 
digestion occurs in the small intestine [147].   The pyloric sphincter opens and allows the 
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chyme to pass into the duodenum where the stomach acids will be neutralized by sodium 
bicarbonate produced by the pancreas.  Once in the small intestine, fat will promote the 
release of CCK from the intestinal I-cells which will bind to receptors on the gallbladder 
to stimulate the release of bile salts and to receptors on pancreas to stimulate the release 
of pancreatic lipase and co-lipase.  In the duodenal lumen the bile salts will insert 
themselves into the emulsion oil droplet, which will expose the sn-1 or sn-3 fatty acids at 
the lipid-water interface.  Colipase activates pancreatic lipase, which will cleave two 
fatty acids at the sn-1 and sn-3 positions of the glycerol backbone leaving two FFAs and 
sn-2-monoacylglycerol.  Similarly pancreatic lipase also hydrolyzes phospholipids 
(mainly phosphatidyl-choline) into a diacylglycercol or lysophospholipid and an FFA.  
Cholesterol esters from animal fats also undergo hydrolysis by pancreatic lipase into 
cholesterol and FFA.   
Bile salts promote micelle formation using the hydrolysis products of TAG, 
phospholipids and cholesterol esters.  In micelle form the fatty acids will be absorbed by 
the intestinal mucosa cells located primarily in the duodenum and jejunum.  Since most 
fatty acid absorption takes place in duodenum and the jejenum it remains a dietary and 
food design challenge to delay the absorption of fatty acids so that absorption takes place 
in the ileum.  Therefore it remains a challenge to design food systems that can modify 
lipid digestion such that the lipids are reaching the ileum intact.  Emulsions have been 
utilized as one such lipid delivery system with the potential to modify lipid digestion 
[148].   
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Emulsions and Their Potential as a Lipid Delivery System 
An emulsion is a food system in which there is a mixture of two or more 
immiscible liquids in which one liquid is dispersed in the other, separated by a boundary 
known as the interface. The interface is stabilized by an amphipathic molecule known as 
an emulsifier and is a common component of food systems (i.e. mayonnaise, butter, 
cakes, milk).  Examples of commercial emulsifiers include, lecithin, sodium stearoyl 
lactylate, and proteins such as casein due to their hydrophobic and hydrophilic 
properties.  Several studies investigating the effects of orally consumed emulsions, 
demonstrated a reduction in appetite and subsequent energy intake [149-151].    
To formulate an emulsion-based lipid delivery system, several factors have to be 
considered since any orally consumed emulsion will undergo many physical and 
chemical changes upon GI tract traversal.  Factors such as pH, ionic composition, 
surface-active components, enzyme activity, and temperature are all considerations when 
designing an emulsion-based delivery system [152].  
An important factor in controlling the rate of lipid digestion is the inhibition of 
pancreatic lipase, which prevents the hydrolysis of TAGs into FFAs and glycerol.  Other 
factors to control the lipid digestion rate include, ingredient interactions such as dietary 
fiber-bile interactions, and mass transport barriers where lipid droplets are encapsulated 
within hydrogel beads, which decrease the rate of diffusion.  Emulsions may influence 
lipid digestibility by several factors: droplet size, droplet lipid composition and the 
choice of emulsifier.   
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Droplet size potentially affects lipid digestion.  Several studies demonstrated that 
the lipid digestion rate is increased with decreasing droplet size [153-156].  However, 
one study demonstrated that emulsions stabilized by -lactoglobulin decreased the 
digestion rate with decreasing droplet size.  It was suggested that the smaller -
lactoglobulin emulsions would be coated by a thicker layer of aggregated globular 
protein on smaller droplets.  These findings demonstrated that the structure of the oil-
water interface plays a role in lipid digestion [157].  
Lipid composition of droplets is another consideration in formulating an 
emulsion-based delivery system.  Examples of composition differences include 
digestible versus non-digestible oils, TAG oils versus essential oils, as well as fatty acid 
chain lengths and/or degree of unsaturation.  Several studies demonstrated that long 
chain TAGs are known to digest at rate slower than medium chain TAGs since the long 
chain TAGs have a tendency to accumulate at the oil-water interface, while medium 
chain TAGs interact more favorably with the surrounding aqueous environment [158, 
159].   Thus, lipid composition plays an important role in decreasing or increasing the 
rate of lipid digestion.   
The choice of emulsifier is another significant consideration in formulating an 
emulsion-based delivery system.  It was demonstrated in one study that emulsions 
formulated with phospholipid emulsifiers underwent more rapid digestion than 
emulsions formulated with proteins as emulsifiers [160].  Another study demonstrated 
that the rate of lipid digestion was lower for emulsion droplets initially coated by 
monoglycerides, than those coated by proteins or phospholipids [161].  Emulsions 
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formulated with galactolipids as emulsifiers from oat oil demonstrated a reduction in the 
rate of lipolysis by inhibition of the binding of pancreatic colipase and lipase at the oil-
water interphase in the duodenum [148].  Another study demonstrated that galactolipids 
from an oat oil emulsion promoted the formation of needle-shaped fatty acid crystals that 
dissolved gradually while traversing the GI tract.  The oat oil emulsion treatment yielded 
significantly greater quantities of fatty acids in the jejunum compared with a milk fat 
control treatment.  The authors suggested that the fatty acids crystals formed from the 
oat oil emulsion could function as a “slow-release capsule” that could potentially 
increase fatty acid exposure to the ileum, triggering the ileal brake [133].   
It should be noted that many food based emulsions are formulated with multiple 
emulsifiers. The primary emulsion is formed by combining an emulsifier such as lecithin 
(phospholipid) or mono/diacylglycerol with the oils and then combined with water.  
Once the primary emulsion droplets are formed, a secondary oppositely charged 
emulsifier (often casein) is added to the droplet to form the secondary emulsion, further 
increasing emulsion stability.  
 While droplet size, lipid composition and emulsifier choice aid in the formulation 
of an emulsion-based delivery systems, it is important to note that the interfacial 
composition of an emulsion changes as it traverses the GI tract.  Individual genetic 
variation affects how emulsions might interact with bile salts, FFAs or phospholipids.  
All of which may affect the rate of lipid digestion.  Nevertheless, it was demonstrated 
that emulsion-based lipid delivery systems have the potential to modify lipid digestion 
where FFA exposure to the ileum is increased, promoting ileal brake activation.  
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However, in order for emulsions to have potential as a satiety inducing ingredient, an 
appropriate food system for delivery must be formulated, followed by subjective and 
objective evaluation to ensure that the treatments are indistinguishable to human 
subjects.   
 
Subjective and Objective Analysis of Food Systems 
Subjective and objective analysis of a formulated food system are two key 
components in the formulation of food products that are combined with satiety inducing 
ingredients.  Subjective analysis includes sensory evaluation of a food system using 
panelists, while objective evaluation of a food system employs laboratory 
instrumentation to measure the physical, visual and chemical parameters of a food 
system. 
Subjective tests are sensory evaluations of a food product that require recruitment 
of panelists to assess the quality and characteristics.  Sensory testing may involve 
describing food color, texture, flavor, aftertaste, astringency or aroma utilizing the five 
senses of touch, sight, odor, taste and even sound.  The three classes of sensory testing 
most commonly administered are affective, discrimination and descriptive tests.  Each 
test serves a different purpose in product quality assessment.  
Affective tests quantify the degree of liking or disliking of one product.  They are 
administered using untrained panelists who are recruited to represent the typical 
consumer of the product of interest.  Examples of affective tests, include the consumer 
acceptance test which provides a rating to individual attributes of a food system that 
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consumers rank on a scorecard.  Examples of sensory attributes that can be ranked are 
the pleasantness, visual appeal, the smell/odor and the taste on a 1-10 scale in 
accordance to previously published methodology [162-164].  
Discrimination tests are administered using untrained panelists to determine if 
any difference exists between two products.  The two products being tested usually 
possess minor ingredient differences and/or formulations.  One such discrimination test 
is the triangle test.  During a triangle test, panelists are presented with one different and 
two identical samples on a tray.  The panelists are instructed to identify the different 
sample.  Each sample is labelled with a random 3-digit code to minimize bias.  The 
triangle test is useful in determining if differences in formulations of a food system may 
produce an overall difference but no specific flavor, color or texture attributes were 
identified as being affected [165]. 
Descriptive tests require highly trained panelists and seek to describe specific 
product attributes related to, but not limited to, flavor, texture, astringency or viscosity.  
Panelists rate the intensities of specific sensory characteristics to define flavor and 
texture profiles of a food system [165].  Descriptive analysis is the most comprehensive 
and information-specific means of providing sensory feedback on a food system. 
Objective evaluation of a food system employ laboratory instrumentation to 
analyze physical, chemical and visual attributes such as viscosity, pH and Hunter L, a, b 
color.  Viscosity is a measure of a food system’s resistance to gradual deformation by 
shear stress.  The viscosity is calculated by dividing the shear stress, the force acting in 
the plane of a fluid, by the shear rate, the velocity experienced by the fluid between 
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moving planes.   It is an important characteristic of a food system that affects texture, 
appearance and mouthfeel.  The viscosity of a food system is typically classified as 
being either Newtonian or Non-Newtonian.  The viscosity of a Newtonian food system 
remains constant at a given temperature and shear stress regardless of shear rate.  Water 
and honey are examples of Newtonian food systems.  The viscosity of a Non-Newtonian 
food system fluctuates depending on the shear rate.  Examples of non-Newtonian foods 
may include ketchup, mayonnaise and yogurt.   
pH is the measure on a 1-14 logarithmic scale of a solution’s acidity or alkalinity 
(basicity).  pH is calculated as the negative log of the hydrogen ion concentration.  Any 
solution with a pH below 7 is considered acidic and any solution with a pH above 7 is 
considered alkaline or basic.  Formulating and processing to stable pH is a key quality 
parameter of a food system that is necessary to preserve flavor, texture and color.  If the 
pH decreases, a sour flavor may form due to protonation of weak acids, affecting the 
mouthfeel and the texture.  The pH may impact the color of the food system due to the 
chemical alteration of pigment molecules.  Therefore, ensuring that the pH is consistent 
between treatments and remains stable over a period of time is critical in the 
development of a food system.   
The color of a food system is a critical visual indicator and is closely related to 
the consumer perception of quality.  Food color is determined by the presence of specific 
pigment molecules in the food system, and may be affected by changes in pH, texture or 
microbial growth.  The Hunter L, a, b, scale measures the specific color values and is 
often used to provide an analysis of color and can detect changes in color over time.  The 
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“L” scale measures light vs. dark where a low number (0-50) is toward dark, 0 being 
black, and a high number (51-100) indicates light, 100 being white.  The “a” scale 
measures red vs. green where a positive number indicates “redness” and a negative 
number indicates “greenness” in a product.  The “b” scale measures yellow vs. blue 
where a positive number indicates “yellowness” and a negative number indicates 
“blueness.”  Ensuring that color is consistent and remains stable over a period of time is 
critical in the quality assessment of a food system.   
In a blind placebo satiety study, the food system should be formulated such that 
there are no statistically significant objective or subjective differences among the 
treatments that may otherwise influence satiety or subsequent energy intake.  
 
Overview of Relevant Satiety Studies  
There have been many satiety studies over the past several decades that have 
tested the effects of various weight loss supplements/satiety agents on human subjects.  
This section will emphasize the satiety studies that are most relevant to the research in 
this dissertation.   
Several studies by Burns et al. investigated the effects of a yogurt supplemented 
with OlibraTM, a fat emulsion composed of a 95:5 palm:oat oil ratio.  Much of the 
research detailing how OlibraTM was formulated and the rationale for the choice of oils 
and composition remain unpublished.  In their first study, Burns et al. investigated the 
short term effects of OlibraTM on energy and macronutrient intake in only non-obese 
subjects (BMI < 30) [150].  The study involved two double-blind, placebo-controlled, 
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within-subject crossover phases that were conducted three months apart.  Twenty-nine 
(15 female, 14 male) subjects participated in the first phase and thirty (16 female, 14 
male) subjects participated in the second phase.  In each phase, subjects were given in 
random order, seven days apart, either a treatment was composed of 200g yogurt + 6g of 
OlibraTM or the control treatment composed of 200g yogurt + 6g of milk fat at 1:00pm on 
the test day.  Four hours post-consumption subjects were given ad libitum access to a 
range of foods. The amounts of food consumed by subjects was determined by pre- and 
post-covert weighing of individual serving dishes.  The results demonstrated that mean 
energy intakes were significantly lower after consumption of the OlibraTM treatment 
compared with the control treatment for both phases. The corresponding fat, protein and 
carbohydrates in both phases were significantly reduced for the OlibraTM compared to 
the control treatment.  They concluded that the possibility exists that the 
physicochemical characteristics of small amounts of fat can potentially affect short-term 
satiety [150].   
For their second study, Burns et al. investigated the effects of OlibraTM on energy 
and macronutrient intakes in non-overweight, overweight, and obese subjects at four and 
eight hours post-consumption.  They conducted a randomized double-blind, placebo-
controlled, within-subject crossover study comparing an emulsion treatment and a 
control treatment.  The emulsion treatment was composed of 200g yogurt + 6g of 
OlibraTM, while the control treatment was 200g yogurt + 6g of milk fat.  Twenty (10 
male, 10 female) non-overweight (BMI 20-24.9 kg/m2), twenty (10 male, 10 female) 
overweight (BMI 25-29.9 kg/m2) and twenty (7 male, 13 female) obese (BMI > 30 
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kg/m2) subjects for a total of 60 subjects participated in the study.  Subjects were given 
in random order, seven days apart, either the emulsion treatment or control treatment 
starting at 9:00am on the day of the study.  At four and eight hours post-consumption 
subjects were given ad libitum access to a range of foods. Amounts of food consumed 
were determined by pre and post-covert weighing of individual serving dishes.  Over the 
following 24 hours, subjects weighed and recorded all food intakes.  The results showed 
that mean energy intakes were significantly lower for the emulsion treatment compared 
with the control in non-overweight and overweight subjects, four hours post-
consumption and in all subjects eight hour post-consumption.  Macronutrient intakes 
were also significantly reduced in non-overweight and overweight subjects at four hours 
post-consumption and in all subjects eight hours post-consumption.  They concluded that 
OlibraTM has the potential to reduce mean energy intakes up to eight hours post-
consumption and concluded that the OlibraTM was likely exerting its satiety effects via 
activation of the ileal brake [149].   
For their third study, Burns et al. investigated if the energy and macronutrient 
intake responses to OlibraTM were dose-dependent and if that effect could be maintained 
for up to 36 hours in non-overweight subjects (BMI 20-24.9 kg/m2) using single-blind, 
placebo-controlled, within-subject cross-over design [151].  Fifty subjects, consisting of 
thirty female and twenty males, participated in the study.  Each subject was studied on 
four occasions, on the same day of the week in a randomized treatment order in one-
week intervals.  Subjects were provided a 200 gram portion of yogurt containing either 
0, 2, 4, or 6 gram quantity of OlibraTM at 9:00am on each study day.  The 0 g quantity 
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served as the control treatment.  At 1:00pm subjects were given ad libitum access to a 
range of foods.  Amounts of food consumed were measured by covert pre- and post-
consumption weighing of individual serving dishes.  For the remainder of the day and 
the following 24 hours, subjects weighed and recorded all food intakes.  Compared to 
the control yogurt, mean energy intakes were progressively reduced with increasing 
doses of OlibraTM fat.  Energy and macronutrient intakes for the remainder of each study 
day and over the following 24 hours were significantly lower after all dose levels 
compared to the control.  Their results suggest that OlibraTM reduced the effect of 
overeating during an ad libitum lunch meal and subsequent food intake up to 36 hours 
post-consumption [151].   
Logan et al. investigated the effect of Olibra on medium-term food intake and 
appetite in twenty-eight (14 male, 14 female) non-obese subjects (BMI > 30 kg/m2) 
using a double-blind, placebo-controlled, within-subject crossover [166].  The emulsion 
treatment was composed of 200g yogurt + 5g of OlibraTM, while the control treatment 
was 200g yogurt + 5g of milk fat.  Subjects were randomly assigned to receive either the 
treatment or control for breakfast for two three week study phases, separated by a three 
week interval.  On days 1, 8 and 22 of the study phases, food intake was assessed by pre- 
and post-covert weighing at an ad libitum buffet-style test lunch, four hours post-
consumption of treatments.  Throughout each of these study days, appetite was assessed 
using visual analogue scales at regular intervals.  For the remainder of the study days, 
and the following 24 hours, subjects reported their food intake using dietary records.  
The results showed that consumption of the OlibraTM treatment had no significant effect 
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on mean energy, macronutrient or amounts of food consumed at the lunch four hours 
post-consumption.  Self-reported food intakes indicated that there was no significant 
reduction of food intakes for the OlibraTM treatment.   There was no consistent effect of 
the OlibraTM treatment on appetite ratings.  In contrast to results demonstrated by Burns 
et al, there was no evidence of a short- or medium-term effect of the OlibraTM treatment 
on food intake or appetite.  Logan et al. suggested that their results could be owing to 
numerous confounding factors that influence eating behavior. 
K. Diepvens et al. assessed the effects of OlibraTM on weight maintenance after 
weight loss including effects on body composition, resting energy expenditure (REE), fat 
oxidation, hunger feelings and satiety hormones using a randomized, placebo-controlled, 
double-blind, parallel design in fifty overweight women (BMI 25-32 kg/m2) [167].  The 
study involved a six week weight loss period that was followed by eighteen weeks of 
weight maintenance.  The emulsion treatment was composed of 200g yogurt + 5g of 
OlibraTM, while the control treatment was 200g yogurt + 5g of milk fat.  In weeks 1, 7 
and 25, VAS satiety questionnaires were administered and blood samples were collected 
for analysis of satiety hormones.  In weeks 2, 8 and 26, REE, body weight and BMI were 
recorded.  The results demonstrated that during the weight maintenance phase after 
significant body weight reduction, there was no significant increase in body weight for 
the OlibraTM treatment group, while the control treatment group gained weight. 
Compared to the control treatment group, the OlibraTM treatment group demonstrated 
significantly less hunger four hours post-consumption in week 25 and showed 
significantly increased GLP-1 values 180 minutes post-consumption.  They reported that 
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measured REE as a function of fat-free mass (FFM) was significantly higher than 
predicted REE in week 26 for the OlibraTM treatment group, but not for the control 
treatment group.  Fat mass was significantly more decreased in the OlibraTM treatment 
group compared to the control treatment group.  They also reported that consumption of 
the OlibraTM treatment improved weight maintenance compared to placebo, which can 
be explained by the relatively higher REE as a function of FFM, relatively higher 
decrease in FM and the relatively lower increase in hunger.  Overall, the authors 
concluded that the OlibraTM treatment improved weight maintenance compared to the 
control treatment [167].  These results were not consistent with the later work of Olsson 
et al. who reported that the addition of OlibraTM treatment to a meal-replacement diet 
plan resulted in 0.9% decrease in BMI, but there was not a significant difference in 
bodyweight change for the OlibraTM treatment compared to the milkfat treatment [168]. 
K. Diepvens et al. also conducted a study examining the short term effects of 
OlibraTM on satiety and energy intake using a randomized, double-blind, placebo-
controlled, crossover design.  The study consisted of forty one total subjects divided into 
two weight categories: twenty one normal weight (~BMI 22.0 kg/m2) and twenty 
overweight (~BMI 27.7 kg/m2).  The OlibraTM treatment was composed of 200g yogurt 
+ 5g of OlibraTM, while the control treatment was 200g yogurt + 5g of milk fat.  VAS 
satiety questionnaires were administered on each visit with a one week interval between 
treatments.  They reported that in the normal weight subjects, consumption of OlibraTM 
treatment reduced hunger and desire to eat during the morning.  No significant 
differences in appetite scores between the OlibraTM treatment and the control treatment 
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were seen for the overweight subjects.  No effect on energy intake was seen in the total 
group, in the junior-normal weight and senior-overweight subjects.  The authors 
concluded that the OlibraTM treatment exerted a suppressive effect on appetite ratings for 
over three hours in normal weight women aged and that consumption of OlibraTM 
treatment did not affect subsequent energy intake in either group [169].  
A study by Haenni et al. is one of the few studies that specifically examined 
whether examined OlibraTM was exerting its effects on satiety and energy intake via 
activation of the ileal brake.  They examined whether consumption of the OlibraTM 
treatment had an effect on orocecal transit time (OCTT) in healthy men using a 
controlled, double-blind, cross-over-designed study in fifteen healthy men (BMI 22-28).  
Subjects were provided both the OlibraTM treatment that was composed of 200g yogurt + 
5g of OlibraTM, or the control treatment was 200g yogurt + 5g of milk fat in randomized 
order separated by one week intervals.  OCTT was determined by following blood 
sulfapyridine levels, a metabolite of salazopyrine in the colon.  Orally consumed 
salazopyrine serves as a marker for OCTT since it is poorly absorbed in the 
gastrointestinal tract, but is rapidly absorbed in the colon upon being hydrolyzed by 
microflora.  The results showed that there was a statistically significant delay in the 
emergence of sulfapyridine in serum after consumption of the OlibraTM treatment versus 
control treatment, demonstratung a greater OCTT due to fat emulsion consumption.  The 
authors concluded that their study provided the first evidence to suggest that OlibraTM 
may affect the ileal brake mechanism by delaying the gastrointestinal transit time [170].  
Similar findings were reported by Knutson et al. who hypothesized that the effects 
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observed could be due to the presence of fat crystals in the jejunum that occurred for 
subjects who consumed the OlibraTM treatment [133].   
Chan et al. examined the effect of OlibraTM on satiety and short-term food intake 
under a range of dietary conditions in contrast with previous studies where OlibraTM was 
combined with yogurt to serve as the test treatment [171].   This was controlled, double-
blind, cross-over-designed study that involved eighteen lean men (BMI 18–25 kg/m2) 
who received six treatments in a randomized order: (i) lipid emulsion, LE (15 g 
OlibraTM, containing 4.2g lipid, 0.2 MJ)+water, (ii) lipid control, LC (15 g non-
emulsified lipid/water, containing 4.2g lipid, 0.2 MJ)+water, (iii) lipid 
emulsion+yoghurt, LE+Y (1.2 MJ), (iv) lipid control+yoghurt, LC+Y (1.2 MJ), (v) lipid 
emulsion+muffin, LE+M (1.2 MJ), (vi) lipid control+muffin, LC+M (1.2 MJ), each 
given as a test breakfast at 8.30 am.  They administered the emulsion along with 185 mL 
water, stirred into a semi-liquid dairy yoghurt, and co-presented with a solid food 
breakfast muffin to determine whether OlibraTM enhances satiety and suppressed short-
term food intake under different dietary conditions.  Subjects completed VAS 
questionnaires, and ad libitum energy intake was measured at a lunch meal 3.5 hours 
post-consumption.  OlibraTM increased satiety compared to iso-caloric lipid control but 
only when administered with yogurt.  There were no effects on satiety ratings when co-
presented with water or with the solid food muffin.  Energy and macronutrient intake 
were not significantly decreased by any of the emulsion treatments.  They demonstrated 
that though the effects were small, the format in which OlibraTM is consumed influences 
satiety, and there is no evidence that OlibraTM alters eating behavior at the subsequent 
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meal.  The authors concluded that yogurt may play a synergistic role when consumed 
with OlibraTM in suppressing appetite [171].   The authors do not speculate as to why 
such may be the case, but yogurt is highly viscous, contains proteins that may aid in 
emulsion stabilization and has been shown to decrease appetite [172].  
In the most recent study examining the effects on satiety and energy intake 
Rebello et al. determined if OlibraTM in conjunction with a healthy diet resulted in 
weight reduction that is associated with energy intake reduction.  The study was 
conducted over 12 weeks as randomized, placebo-controlled, double-blind, parallel trial 
that measured the effects of Olibra™.  The OlibraTM treatment was composed of 200g 
yogurt + 2.1g of OlibraTM, while the control treatment was 200g yogurt + 1.95g of milk 
fat.  The OlibraTM treatment or milk fat control treatment were administered twice daily, 
and the effects on food intake, appetite, satiety, weight, and body composition.  Eighty-
two subjects (number of males and females were not reported) were recruited (BMI 25-
40 kg/m2).  Subjects were required six total visitations to the clinic: day -7 (visit 1), day 
0 (visit 2), day 14 (visit 3), day 28 (visit 4), day 56 (visit 5) and day 84 (visit 6).  On 
days -7, 0, and 28, OlibraTM or milkfat treatment served as breakfast and lunch.  Food 
intake, appetite, and satiety were assessed after lunch and dinner.  Body weight was 
measured on all visits.  After 12 weeks, differential group effects were not significant for 
body fat, waist-hip ratio, food intake, appetite, and satiety.  The authors concluded that at 
the administered dose, OlibraTM did not exert a consistent effect on food intake, appetite 
regulation, body weight, or body composition [173]. 
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There is sufficient evidence in the literature demonstrating the effects that 
emulsions, specifically OlibraTM, exert on satiety, energy reduction and ileal brake 
activation [149-151, 166-171, 173].  Although the findings from other studies are not in 
complete agreement [168, 169].  At this time there have been no reported satiety studies 
which examined the effects of fish oil emulsions on satiety or ileal brake activation.  
Fish oil has several properties suggesting it could serve as a potential activator of the 
ileal brake.  Fish oil is comprised of a high amount of long chain (80%) and unsaturated 
fatty acids (55%), both of which have been demonstrated to have a positive effect on 
satiety and ileal brake activation [138-142].  In addition to the potential effect on satiety, 
the omega-3 (n-3) fatty acids are considered anti-inflammatory nutrients, which could 
potentially alleviate the inflammatory response of obesity [174].   Therefore, there are 
multiple health-related benefits in determining if an emulsion containing fish oil can 
induce satiety, a reduction in energy intake and trigger ileal brake activation.  
 
Cell Culture Studies Measuring the Response of Satiety Hormones 
Given the expense and manpower required to conduct human clinical trials, cell 
culture studies utilizing isolated intestinal cells are employed as an alternative to testing 
the effects of nutrients on hormone secretion, specifically PYY and GLP-1.  While 
isolated human intestinal cells provide the best screening model to test effects of 
nutrients on hormone secretions, their isolation is a lengthy process and produces fairly 
low yields.  Because of such difficulties, the STC-1 cell line, derived from an intestinal 
endocrine tumor in a double-transgenic mouse, has been utilized for such studies [175].  
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Cordier Busset et al. demonstrated that addition of protein hydrolysates to the STC-1 
cell medium stimulated GLP-1 secretion and the upregulation of the proglucagon gene 
[176, 177].  Wang et al. demonstrated that luminal CCK-releasing factor promoted CCK 
secretion in STC-1 cells and was confirmed that in a later study using protein 
hydrolysates [177-179].  Saris et al. demonstrated that supplementing the STC-1 cell 
culture medium with FFAs of various length stimulated the secretion of PYY [180].  
Such studies suggest that the STC-1 cell line remains a viable alternative in analyzing 
the response of CCK, GLP-1 and PYY secretion to nutrient supplementation.  Despite 
the advantages in cost and time, the STC-1 model only determines if a specific 
ingredient or satiety agent can promote PYY and GLP-1 secretion and does not 
determine whether such an ingredient/satiety agent can promote satiety in human 
volunteers.   
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CHAPTER II 
EMULSIONS COMPOSED OF FISH OIL AND PALM OIL PROMOTE PEPTIDE YY 
AND GLP-1 SECRETION FROM STC-1 CELLS 
 
BACKGROUND AND RATIONALE 
The goal of phase one was to test the hypothesis that two emulsions composed of 
varying palm oil to fish oil ratios (referred to as fish oil emulsions for simplicity) 
induced glucagon-like-peptide 1 (GLP-1) and peptide-YY (PYY) secretion from STC-1 
cells, a murine enteroendocrine cell line that secretes hormones in a manner that 
resembles intestinal L-cells in humans. 
GLP‑1 is an incretin produced and secreted by the intestinal L-cells of the ileum 
and proximal colon [38-41].  GLP-1 enhances glucose-dependent insulin secretion, 
inhibits glucagon release from the pancreatic -cells and delays nutrient absorption 
through inhibition of gastric emptying and intestinal motility [42-44].  Macronutrient 
binding to receptors on the intestinal L-cells stimulates production and secretion of GLP-
1 into the bloodstream [52-64].  From there GLP-1 will cross the blood brain barrier and 
bind to receptors in the hypothalamic arcuate nuclei to suppress appetite and induce 
satiety [48, 67].  GLP-1 is rapidly degraded by DPP-4 and therefore a sufficient amount 
needs to be produced to exert its effects [65, 66].   
PYY is produced and secreted by intestinal L-cells and exhibits a similar 
inhibitory effect on gastric emptying and jejunal motility as GLP-1 [70].   The exact 
intercellular mechanisms leading to PYY production are still unknown, but upon nutrient 
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stimulation PYY is produced and secreted from the L-cells into the bloodstream where 
PYY is degraded by DPP-4 into its active PYY3-36 form.  PYY3-36 exclusively binds to 
the Y2 receptors expressed in the hypothalamic arcuate nucleus to promote appetite 
suppression and satiety [70-75]. 
Given their role in delaying gastric emptying and inhibiting jejunal motility, 
GLP-1 and PYY are considered biomarkers of the ileal brake, a gastric inhibitory 
feedback mechanism that controls the transit of food through the gastrointestinal tract 
that has been shown to reduce food intake and increase satiety [121-132].  As a result the 
ileal brake has become an attractive target for appetite control.   
STC-1 cells have been shown to secrete GLP-1 and PYY upon ingredient 
supplementation to the cell culture medium in a manner similar to intestinal L-cells [176, 
177, 180].  At the time of writing, there has been no reported study that has examined 
whether an emulsion can stimulate secretion of PYY or GLP-1 in STC-1 cells.  
An emulsion is a mixture of two immiscible liquids in which one liquid is 
dispersed (dispersed phase) in the other (continuous phase).  This mixture is stabilized 
by an emulsifier that contains a hydrophilic head to interact with the water phase and the 
hydrophobic tail to interact with the oil phase.  Example of commercially used 
emulsifiers consist of lecithin, diacetyl tartaric acid ester of mono- and diglycerides 
(DATEM) and casein.  The simplest emulsions are classified as oil in water (O/W) or 
water in oil (W/O).   
The commercial product OlibraTM (Lipid Technologies Provider AB (LTPAB), 
Karishamn, Sweden) is an emulsion composed of a 95:5 ratio of palm oil to oat oil in 
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which the hydrophilic galactolipids derived from oat oil serve as the emulsifier.  
OlibraTM when consumed with yogurt has been previously shown to suppress appetite 
and reduce food intake in clinical studies [149-151].  Much of the research detailing how 
OlibraTM was designed and the justification for using palm oil as the main constituent of 
the emulsion remains unpublished.  However, it is known that in addition to being 
readily available palm oil does possesses high amounts of palmitic acid (~44%) and 
oleic acid (~37%)  both of which had been shown to have potential in activation of the 
ileal brake [138, 139].   
For this specific study two oil in water emulsions that contained varying ratios of 
palm oil to fish oil were prepared and provided by Omega Protein (known previously as 
Omega Pure) a publicly traded company located in Houston, Texas that specializes in 
developing ingredients such as protein, omega-3 fatty acids, and antioxidants that can be 
added to functional foods to improve their nutritional value.  Omega Protein had an 
interest in developing their own emulsion using fish oil extracted from menhaden fish 
instead of oat oil to serve as an alternative to OlibraTM.  Fish oil has several properties 
suggesting it could serve as a potential activator of the ileal brake.  First, over 80% of 
fish oil is comprised of long chain fatty acids, which have been demonstrated to delay 
gastric emptying [138, 139].  Second, fish oil also contains a high amount of unsaturated 
fatty acids (55%) which some studies suggest that a higher degree of unsaturation 
corresponds to a greater effect on satiety, although findings are inconclusive [140-142].  
In addition to the potential effect on satiety, the omega-3 (n-3) fatty acids specifically 
docosahexaenoic acid (DHA-22:6n-3) and eicosapentaenoic acid (EPA-20:5n-3) are 
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considered anti-inflammatory nutrients and have been often been used a dietary 
supplement for inflammatory diseases such as rheumatoid arthritis and cardiovascular 
disease [174].   Therefore, there are multiple health-related benefits to knowing if a fish 
oil emulsion can induce the secretion of GLP-1 and PYY in STC-1 cells.   
If the fish oil emulsions were shown to stimulate GLP-1 and PYY secretion from 
STC-1 cells it would be reasonable to investigate whether oral consumption of fish oil 
emulsions could induce satiety in human volunteers. 
 
EXPERIMENTAL DESIGN 
Emulsion Composition and Preparation 
The emulsions for the beverage were prepared by Omega Pure (Houston, Texas).  
Two emulsions referred to as A and B were tested.  The emulsions differed in their palm 
oil to fish oil ratios, being either 2:1 (A) or 1:1 (B). Table 3 shows the quantities of each 
ingredient used in preparing a 200g emulsion sample. Table 4 presents a description of 
the components used to prepare emulsion A and emulsion B.  Figure 7 shows the 
treatment preparation diagram. 
 
Emulsion A  
2:1 palm oil: fish oil ratio  
Emulsion B  
1:1 palm oil: fish oil ratio 
Ingredient % Amt / 200 g 
 
Ingredient % Amt / 200 g 
Water 66.58% 133.16 g 
 
Water 66.58% 133.16 g 
SansTrans 39 19.58% 39.16 g 
 
SansTrans 39 14.69% 29.38 g 
OP HSN 9.79% 19.58 g 
 
OP HSN 14.69% 29.38 g 
Na-caseinate 1.96% 3.92 g 
 
Na-caseinate 1.96% 3.92 g 
Gum Arabic 1.37% 2.74 g 
 
Gum Arabic 1.37% 2.74 g 
K-sorbate 0.49% 0.98 g 
 
K-sorbate 0.49% 0.98 g 
Panodan 0.23% 0.45 g 
 
Panodan 0.23% 0.45 g 
Table 3 - Quantity of Ingredients Present in Each Emulsion 
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Ingredient Function 
Gum arabic A complex mixture of glycoproteins and polysaccharides that is used primarily in the food 
industry as a stabilizer for the purpose of reducing the surface tension of emulsions. 
 
Panadan A diacetyl tartaric acid ester of mono-diglycerides (DATEM) made from edible, refined 
soybean oil.  Served as the emulsifier to make primary emulsion.   
 
Na-caseinate Proteins derived from milk that are commonly used as food stabilizers.  Used as coating to the 
primary emulsion to form the secondary emulsion. 
 
K-sorbate Served as a preservative against molds and yeasts.  
 
SansTransTM 39 Served as the palm oil portion of the palm oil phase.  Developed by Lokers CroklaanTM and sold 
commercially as multi-bakery shortening based on palm oil and fractions of palm oil.  It has 
been designed as an alternative to shortening due to the fact that it is non-hydrogenated and 
contains no trans-fatty acids.  Melting point is reported to be between 37-41oC and is composed 
of 49.9% of saturated fatty acids, 40.1% mono-unsaturated, and 9.6% polyunsaturated 
according to manufacturer spec sheet.  
 
Omega Pure (OP) 
HSN 
Served as the fish oil portion of the fish oil phase.  Derived from menhaden fish. Composed of 
32% unsaturated fatty acids, 24% mono-unsaturated, 36.74% polyunsaturated (35.66% omega-
3) and 7.12% that is not defined on the sheet.  EPA + DHA composed 26.12% of total fatty acid 
composition.  Also contains tocopherols to serve as antioxidants. 
Table 4 - Ingredients Used in Emulsions 
All of the above ingredients were necessary to prepare a stable emulsion.  Emulsions A and B differed only in the 
amount of SanTransTM 39 and OP HSN 
 
 
 
Figure 7 - Emulsion Preparation Diagram 
Emulsion A and B both differed in the amount of SansTransTM 39 (palm oil) and OP HSN (fish oil) present.  Both oils 
were mixed together plus the DATEM emulsifier to make the oil phase.  The oil phase was mixed with the aqueous 
gum arabic solution to create the primary emulsion.  The primary emulsion was then mixed with the aqueous sodium 
caseinate resulting in the final (secondary) emulsion. 
SansTransTM 39 + 
OP HSN 
+ 
PANADAN 
(Emulsifier)
WATER 
+
GUM ARABIC
WATER 
+
Na CASEINATE
PRIMARY 
EMULSION
SECONDARY
EMULSION
MIX
MIX
Na Caseinate coat
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To prepare the oil phase, both solid SansTransTM 39 (palm oil source) and liquid 
OP HSN (fish oil source) were heated in separate beakers on the same heating plate 
(Corning PC-420D) to 44oC.  The temperature of the oil mixture was monitored using a 
standard thermometer.  A temperature of 44oC was sufficient to completely melt the 
SansTransTM 39 and ensured that mixing of both oils would be uniform.  Both oils were 
combined with a proprietary quantity of rosemary antioxidant and Panodan emulsifier to 
create the oil phase.  Due to confidentiality agreements with Omega PureTM, the exact 
quantity of rosemary extract is unknown.  Panodan, in liquid form, was added to the 
mixture using a 5mL pipette.  The solution was mixed with a stir bar at a speed of 500 
rpm.   
To prepare the water phase, two equivalent water solutions were prepared: one 
that contained dissolved gum arabic and one that contained dissolved sodium caseinate.  
The gum arabic and sodium caseinate were dissolved in distilled water via stir bar 
mixing at a speed of 500 rpm in separate beakers and mixing plates at room temperature.   
Using an Ultra Turrax T 50 Basic shearing mixer (IKA WerkeTM Wilmington, 
NC) the oil phase solution was slowly added to the gum arabic water solution.  The 
shearing speed was gradually increased to maximum as the dispersion became more 
evenly mixed.  After this step, the range of the size of the oil droplets was approximately 
1-10 m. Once the dispersion was sufficiently mixed it was then passed through a 
homogenizer (Niro SoaviTM NS10011 2K Bedford, NH) at 50 Bar to break up larger oil 
droplets and then passed again at 400 Bar to further decrease the oil droplet size down to 
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0.2–2 m with some flocculation.  The resulting dispersion was referred to as the 
primary emulsion as shown in Figure 7. 
Using the Turrax mixer the primary emulsion was gradually added to the sodium 
caseinate solution where the negatively charged caseinate functioned as an emulsion 
stabilizer.  Sodium caseinate can stabilize emulsions by lowering the interfacial tension 
due to its adsorption at the interface.  Similar to the first step the shearing speed of the 
Turrax mixer was gradually increased as the dispersion became more uniform.  The 
resulting dispersion was then passed through a homogenizer at 400 Bar to ensure a 
consistent oil droplet size range of 0.2–2 m with minimal flocculation.  The emulsions 
were examined under a microscope to ensure minimal flocculation and consistent droplet 
size.  The emulsions were sealed and refrigerated at 40C until it was time to for them to 
be added to the cell culture. 
 
Cell Culture  
 The STC-1 hormone secretion assay was performed using a protocol established 
by Geraedts et al [180].  The STC-1 cell line was obtained from ATCC with permission 
granted by Dr. Hanahan from the University of California at San Francisco.  The cells 
were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with high 
glucose (1.5g/L), 1mM sodium pyruvate (Sigma), 1X non-essential amino acids 
(Sigma), 10% fetal bovine serum with penicillin (100units/mL) and streptomycin (100 
ug/ml) in an incubator (ThermoTM Forma Series II) at 37oC in 5% CO2.  Cells were 
passed until there was a sufficient number of cells to seed at least six 24-well plates at 
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~105 cells/well.  Cell counts prior to seeding were measured using MuseTM Cell 
Analyzer made by EMD-Millipore. 
 
STC-1 Hormone Secretion Assay and Analysis  
After 72 hours of incubation in the DMEM medium, the wells were washed three 
times with phosphate buffer saline (PBS) and then incubated (37oC in 5% CO2) with the 
six treatments, all diluted to 1% using Hanks Balanced Salt Solution (HBSS), described 
in Table 5.   
 
Treatment Description Function 
HBSS Hanks Balanced Salt Solution.  Sample diluent. 
 
Negative control. [180].   
1% Emulsifier Solution containing all the emulsion components except for 
the oil phase.  
 
Comparison control. 
1% Palm  Emulsion composed of 100% palm oil for oil phase 
 
Sample with 0.29mg palm oil 
 
1% Fish  Emulsion composed of 100% fish oil for oil phase Sample with 0.29mg fish oil 
 
1% Emulsion A Emulsion composed of 2:1 palm:fish ratio for oil phase 
 
Sample with 0.195mg palm oil, 
0.095g fish oil 
1% Emulsion B Emulsion composed of 1:1 palm:fish ratio for oil phase 
 
Sample of with 0.145mg palm 
oil, 0.145mg fish oil 
Table 5 – Treatment Description 
 
 
 
HBSS served as a negative control as previously described [180].   The 
emulsifier was used as a comparison control to eliminate the possibility that the 
ingredients in the emulsion other than the palm oil or the fish oil could stimulate GLP-1 
or PYY secretion.  Emulsions composed of 100% palm oil and 100% fish oil were also 
utilized to examine their individual effects on GLP-1 or PYY secretion.  1mL of 1% 
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treatment solution was added to each well bringing the total lipid concentration to 
~290g/mL per non-control well.   
Each treatment was arranged in triplicate in a 24 well plate as represented in 
Figure 8.  Each well contained ~105 STC-1 cells upon seeding.   
 
 
Figure 8 - Treatment Arrangement Diagram for 24-well Plate 
Each treatment was vertically arranged in triplicates.  Each well contained ~105 STC-1 cells. 
 
Once the corresponding treatment samples were pipetted into each well, the 
plates were incubated at 37oC in 5% CO2.  There were four total plates with each plate 
representing specific timepoints of 30, 60, 90 and 120 minutes for which the supernatant 
from the wells were collected.  Upon removal, the supernatants from each well were 
pipetted into labelled test tubes and frozen at -20oC until ready for analysis.   
For analysis the treatment samples were thawed on ice and analyzed for GLP-1 
and total PYY using the Metabolism Multiplex Assay kit (EMD-Millipore cat. 
 53 
 
MMHMAG-44K) on the Luminex 200 Multiplexin Instrument according to 
manufacturer’s instructions.  Total PYY (PYY1-36 + PYY3-36) is what is measured since 
DPP-4’s found in bloodstream and is not known to be produced by L-cells or STC-1 
cells nor can the hormone kit discriminate between the two forms.  
 
Statistical Analysis 
Differences in the potency of the emulsions to increase PYY and GLP-1 
secretion in STC-1 cells were analyzed using a two-way analysis of variance (ANOVA).  
Differences were considered to be significant at a p-value < 0.05.  Data are presented as 
the mean ± SEM in Figure 9 and Figure 10.  All experiments were performed in 
triplicate. 
 
RESULTS  
Emulsion Induced GLP-1 Secretion by STC-1 Cells 
There was not a significant GLP-1 induction difference between the emulsifier 
and the HBSS control at any timepoint and therefore the emulsifier can be considered 
non-inducing for GLP-1 secretion (Figure 9).  Palm oil showed the greatest induction of 
GLP-1 secretion at every timepoint with the 60 minute point being the greatest compared 
to the HBSS control (Figure 9).  The fish oil emulsion also showed an increase in GLP-1 
secretion compared to the HBSS control at all timepoints, but was far less pronounced 
than the palm oil emulsion (Figure 9).  For emulsion A (2:1 palm:oil) at all timepoints 
there a significantly greater induction of GLP-1 secretion compared to control with the 
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120 minute timepoint showing the greatest difference (Figure 9).  For emulsion B there 
was a significant increase in GLP-1 secretion at all timepoints compared to the HBSS 
control (Figure 9).  When comparing Emulsion A to Emulsion B, there was not a 
significant difference at the 30 and 120 minute timepoints, but Emulsion B induced 
significantly greater GLP-1 secretion at the 60 and 90 minute timepoints.  It is important 
to note that the palm and fish oil emulsions showed the greatest induction of GLP-1 
secretion at the 30 minute timepoint (Figure 9).   
 
 
Figure 9 - GLP-1 Secretion from STC-1 Cells 
The stimulatory effect of each treatment on GLP-1 secretion was investigated after an incubation period of 30, 60, 90 
and 120 min.  The results are reported as the mean ± SEM (n=3).  Refer to Table 5 for treatment description.  
 
 
Emulsion Induced PYY Secretion by STC-1 Cells 
Similar to GLP-1 secretion there was not a significant difference between the 
emulsifier and the HBSS control at any timepoint and therefore the emulsifier can 
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likewise be considered non-inducing for PYY secretion (Figure 10).  The results for the 
HBSS control show a consistent secretion of PYY at ~11pg/mL at all timepoints which 
is consistent with the previously reported ~16pg/mL [180].  In complete contrast to 
GLP-1 secretion, the palm oil emulsion induced the least amount of PYY secretion with 
the 90 minute timepoint showing the only significant difference compared to control 
(Figure 10).   The fish oil emulsion, as well as emulsion A and emulsion B, all induced a 
10-fold level increase of PYY secretion compared to the HBSS control, which suggests 
that the fish oil present in the emulsions could play a significant role in inducing PYY 
secretion (Figure 10).  
 
 
Figure 10 - PYY Secretion from STC-1 Cells 
The stimulatory effect of each treatment on PYY secretion was investigated after an incubation period of 30, 60, 90 
and 120 min.  The results are reported as the mean ± SEM (n=3).  Refer to Table 5 for treatment description 
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DISCUSSION 
Research is ongoing in the food and drug industry as well as academia to design 
food systems that target the ileal brake as a means to control appetite and counter 
obesity.   OlibraTM is one such emulsion that when combined with yogurt has been used 
for this exact purpose [149-151].  STC-1 hormone secretion assays have been utilized as 
a preliminary model to determine if certain ingredients or components of a food system 
can stimulate GLP-1 and PYY secretion [176-180].   
It has now been demonstrated in our study that emulsions A and B stimulate the 
secretion of GLP-1 and PYY from STC-1 cells.   The underlying mechanisms that both 
emulsions utilize to induce PYY and GLP-1 secretion is not clear.  Based on the results 
and given that the emulsifier treatment fails to induce a significant amount of PYY and 
GLP-1 secretion it is a distinct possibility that the oils themselves are directly 
responsible, but the possibility that the oils work synergistically with the emulsifier also 
exists.  The palm oil emulsion induced the greatest level of GLP-1 secretion, while 
inducing the lowest level of PYY secretion.  Conversely, emulsions A and B as well as 
the 100% fish oil emulsion were able to stimulate both GLP-1 and PYY.  Such a result 
indicates that there are different mechanisms involved in ingredient-induced GLP-1 and 
PYY secretion in STC-1 cells.   Nutrient-stimulated secretion of GLP-1 occurs upon 
nutrient interaction with G-protein receptors (GRP40, GRP43, GRP119, GRP120, 
FATP4 and TGR5) of the intestinal L-cells [52-64].  Specifically, it was demonstrated 
that oleic acid interaction with the FATP4 receptor stimulates GLP-1 secretion [64].  
100% palm oil contains a greater composition of oleic acid (~38%) than emulsions A 
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and B (~28 and ~24%) and it is possible that the palm oil-induced effect is being 
mediated through the FATP4 receptor.  At the time of writing, the mechanism of 
nutrient-stimulated release of PYY has not been elucidated, although our data 
demonstrates that PYY secretion is stimulated by unsaturated fatty acids or even omega-
3 fatty acids to greater effect compared to saturated fatty acids.  It is worth noting that it 
was previously reported that saturated fatty acids of chain length of 4, 12, 14, 16 and 18 
carbons dispersed in HBSS stimulate PYY secretion upon addition to STC-1 cells at 
concentrations of about 30-40 pg/mL compared to the ~160-170 pg/mL range that was 
shown in our study for emulsions A and B [180].  This further supports the possibility of 
unsaturated fatty acids being more potent inducers of PYY secretion.  Examining 
individual unsaturated fatty acids following the previously reported method could help 
clarify the situation regarding this effect [180].  Emulsions A and B were able to 
significantly increase secretion of GLP-1 and PYY in far greater amounts compared to 
control, which suggests that there is potential for the emulsions to serve as activators of 
the ileal brake when consumed.  
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CHAPTER III 
SENSORY AND RHEOLOGICAL CHARACTERISTICS OF A PREPARED 
BEVERAGE TO SERVE AS VEHICLE FOR SATIETY INDUCING EMULSIONS  
 
BACKGROUND AND RATIONALE 
In the first phase of this research it was shown that two emulsions referred to as 
emulsion A and emulsion B composed of different ratios of palm and fish oil induced the 
secretion of the hormones GLP-1 and PYY from STC-1 cells, a murine enteroendocrine 
cell line capable of secreting hormones in a manner similar to humans.  In humans, GLP-
1 and PYY are considered biomarkers for the ileal brake.  The ileal brake is a gastric 
inhibitory feedback mechanism that controls the transit of food through the 
gastrointestinal tract that has been shown to reduce food intake and increase satiety, 
making it an attractive target for appetite control [121-132].  Since both emulsion A and 
emulsion B were shown to induce the secretion of PYY and GLP-1 in STC-1 cells, a 
distinct possibility exists that both emulsions have the potential to serve as satiety 
inducing agents when orally consumed.   
In recent years, beverages blended with a combination of fruit and dairy products 
known as smoothies have been promoted as a healthy beverage option that can serve as a 
meal replacement or as a between meal snack.  These have become a popular choice 
among consumers [181].  Smoothies are perceived as having less calories than solid 
foods because of their fluid texture, making them an attractive option for individuals 
concerned with weight management [182-184]. 
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The beverage developed in this study is a functional food, and was formulated 
using skim milk, bananas, Adams vanilla extract, Jell-O Brand vanilla flavored sugar 
and fat free powdered pudding, Hershey’s chocolate syrup, fresh strawberries, 
McCormick cinnamon, and Horizon Fat Free Organic Yogurt, as shown in Table 8.  This 
formulation is an enrichment of the yogurt that served as the vehicle for OlibraTM from 
previous studies [149-151].  All ingredients were fat-free to ensure that the emulsions 
and the milkfat control represented the only source of fat.  Yogurt was chosen since it is 
has been shown to serve as an effective vehicle in previous studies that involved using 
emulsions as an appetite suppressing ingredient [149-151].  Skim milk was chosen to 
disperse the ingredients.  Milk also contains casein that could potentially aid in 
emulsification and contribute to mouthfeel [185].  Jell-O pudding, in addition to flavor 
and texture, contains the emulsifier sodium stearoyl lactylate (SSL) and sodium alginate 
which is a hydrocolloid that functions as an emulsifier and increases viscosity.  In 
combination, these may improve overall emulsion stability [186, 187].  Cinnamon and 
vanilla extract were added to enhance the beverage flavor.  Hershey’s chocolate syrup 
provide flavor and was the primary contributor to the color of the beverage.  Hershey’s 
chocolate syrup contains high fructose corn syrup (HFCS) with an unspecified ratio of 
glucose to fructose.  It has been reported that hunger, satiety, or short-term energy 
intakes are not significantly different when comparing beverages sweetened with either 
sucrose or HFCS [112].  Banana and strawberries, the fruit component of the beverage, 
contributed to flavor, nutrients, texture and viscosity.   
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In the second research phase, which is the focus of this report, a smoothie 
beverage, containing emulsions to deliver them to the digestive tract to induce PYY and 
GLP-1 secretion, was prepared using locally purchased fresh ingredients shown in Table 
7.  Each prepared beverage was supplemented with one of the two emulsions or milkfat 
control.  The beverage combined with the milkfat control was referred to as the control 
treatment, while the beverage combined with emulsion A was referred to as treatment A 
and treatment B for emulsion B.  The beverages were formulated with the goal of 
eliminating subjective and objective variations among treatments.  Figure 11 outlines the 
objective and comparison tests performed for each treatment.   
 
 
Figure 11 - Outline of Emulsion Treatment Comparison Tests 
Control treatment refers to the beverage supplemented with the milkfat control, while treatments A and B refer to the 
beverage supplemented with emulsions A and B.  Emulsions A and B differ in their ratios of palm and fish oil.  
Emulsion A has a 2:1 palm:fish oil ratio, while emulsion B has a 1:1 palm:fish oil ratio.  Objective and Subjective 
tests determined if there were any differences between treatments. 
 
 
 
Subjective sensory tests and objective instrumental analysis were performed on 
each treatment and the results were statistically analyzed using an ANOVA.  For the 
subjective sensory tests, triangle tests and acceptance/affective tests were administered 
using untrained consumers.  The triangle test was utilized to determine if there was a 
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sensory difference between each emulsion treatment compared to milkfat control.  The 
triangle test is useful when treatment effects of a food system may produce an overall 
difference but no specific flavor, color or texture attributes can be identified as having 
been affected [165].  While the triangle test is useful in determining an overall 
difference, the acceptance/affective tests rank or otherwise determine if there are 
individual attributes of a food system that are different using a scorecard.  In our study, 
subjects ranked the overall pleasantness, visual appeal, the smell/odor and the taste on a 
1-10 scale in accordance to previously published methodology [162-164].  
The objective tests employed laboratory instrumentation to analyze and compare 
the viscosities, pH and Hunter L, a, b color values of each treatment.  Viscosity is a 
measure of a food system’s resistance to gradual deformation by shear stress and is an 
important characteristic of a food system that affects texture, appearance and mouthfeel.  
In addition, research has shown that foods of higher viscosity may positively influence 
satiety [188-190].   
Formulating and processing to stable pH is a key quality parameter of a food 
system that is necessary to preserve flavor, texture and color.  If the pH decreases, a sour 
flavor can form due to protonation of weak acids.  If the pH decreases below 4.6 (the pI 
of casein) the casein from the milk and the emulsion in the beverage will coagulate and 
precipitate.  This affects the mouthfeel and the texture.  The pH also potentially impacts 
pigment molecules, hence the color of the food system.  Therefore ensuring that the pH 
is consistent between treatments and remains stable over a period of time is critical in the 
development of a food system.   
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The color of a food system is a critical visual indicator and is closely related to 
the consumer perception of quality.  Food color is due to presence of specific pigment 
molecules in the food system, and may be affected by changes in pH, texture or 
microbial growth.  Ensuring that color is consistent and remains stable over a period of 
time is critical in the quality assessment of a food system.  The Hunter L, a, b, scale 
measures the specific color values and is often used to provide an analysis of color and 
can detect changes in color over time.  The “L” scale measures light vs. dark where a 
low number (0-50) is toward dark, 0 being black, and a high number (51-100) indicates 
light, 100 being white.  The “a” scale measures red vs. green where a positive number 
indicates “redness” and a negative number indicates “greenness” in a product.  The “b” 
scale measures yellow vs. blue where a positive number indicates “yellowness” and a 
negative number indicates “blueness.”   
All of the aforementioned subjective sensory tests and objective instrumental 
analyses are necessary to test the hypothesis that the formulated fruit and dairy 
smoothie-type beverage could serve as vehicle for the satiety emulsions in human 
volunteers.   
 
METHODS 
Treatment Preparation 
Beverage ingredients excluding the emulsions were purchased from an H.E.B. 
supermarket located in College Station, Texas on a weekly basis in order to ensure 
consistency and freshness for each experiment as much as possible.  The treatments were 
 63 
 
freshly prepared prior to each subjective and objective comparison test.  Milkfat from 
heavy whipping cream served as the control in accordance to previous studies [149-151].   
 
(a) 
 Carbohydrates 
(g) 
Sugar 
(g) 
Fiber 
(g) 
Starch 
(g) 
Fat 
(g) 
Protein 
(g) 
Kilocalories 
Banana 14 8.74 1.38 3.68 0 0.46 50.6 
Vanilla 0 0.23 0 0 0 0 5.52 
Fat Free Vanilla 
Pudding 
1.2 0 0 1.15 0 0 4.6 
Hersheys Syrup 11 9.2 0.46 1.38 0 0.46 46 
Strawberries 1.3 0.81 0.32 0.16 0 0.161 5.15 
Skim milk 2.8 2.76 0 0 0 1.84 19.78 
Yogurt 3.5 3.45 0.23 0 0 2.53 25.3 
Total (pre-treatment) 33 25.2 2.4 6.4 0 5.5 157.0 
         
(b) 
Milkfat (control) (6g) 0 0 0 0 1.8 0.1 16.6 
Emulsion A (6g) 0 0 0 0 1.8 0.1 16.6 
Emulsion B (6g) 0 0 0 0 1.8 0.1 16.6 
Total with treatment 33 25.2 2.4 6.4 1.8 5.5 173.2 
Table 6 - Macronutrient Composition of Treatments 
Macronutrient composition was estimated using food nutrition labels.  (a) refers to the beverage only and (b) refers to 
the emulsions.  The Strawberry and banana composition was estimated using Dole’s nutrition website.  The control is 
composed of milkfat from heavy whipping cream. 
 
 
  
All of the ingredients were combined into a blender (Oster 14 Speed, Rye, NY) 
and set on the lowest speed (setting “stir”) for one and a half minutes.  The resulting 
treatments had a brown appearance and viscous texture (Figure 12).   
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Figure 12 – Visual Representation of Each Treatment 
The above picture was taken after treatment preparation and is intended to provide a visual representation of the color 
and viscosity. 
 
 
 
Emulsion Composition and Preparation 
The emulsions for the beverage were prepared by Omega Pure (Houston, Texas).  
Two emulsions which were referred to as A and B were tested.  The emulsions differed 
in their palm oil to fish oil ratios, being either 2:1 (A) or 1:1 (B).  Table 7 shows the 
quantities in grams of each ingredient present in a six gram sample emulsion, the amount 
added per 200g of beverage.  Table 8 presents a description of the components used to 
prepare emulsion A and emulsion B.  Figure 13 shows the treatment preparation 
diagram. 
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Emulsion A  
2:1 palm oil: fish oil ratio  
Emulsion B  
1:1 palm oil: fish oil ratio 
Ingredient % Amt / 6g 
 
Ingredient % Amt / 6g 
Water 66.58% 4g 
 
Water 66.58% 4g 
SansTrans 39 19.58% 1.2g 
 
SansTrans 39 14.69% 0.9g 
OP HSN 9.79% 0.6g 
 
OP HSN 14.69% 0.9g 
Na-caseinate 1.96% 0.1g 
 
Na-caseinate 1.96% 0.1g 
Gum Arabic 1.37% 0.1g 
 
Gum Arabic 1.37% 0.1g 
K-sorbate 0.49% ~0g 
 
K-sorbate 0.49% ~0g 
Panodan 0.23% ~0g 
 
Panodan 0.23% ~0g 
Table 7 - Quantity of Emulsion Ingredients Present in Each Treatment 
 
 
Ingredient Function 
Gum arabic A complex mixture of glycoproteins and polysaccharides that is used primarily in the food 
industry as a stabilizer for the purpose of reducing the surface tension of emulsions. 
 
Panadan A diacetyl tartaric acid ester of mono-diglycerides (DATEM) made from edible, refined 
soybean oil.  Served as the emulsifier to make primary emulsion.   
 
Na-caseinate Proteins derived from milk that are commonly used as food stabilizers.  Used as coating to the 
primary emulsion to form the secondary emulsion. 
 
K-sorbate Served as a preservative against molds and yeasts.  
 
SansTransTM 39 Served as the palm oil portion of the palm oil phase.  Developed by Lokers CroklaanTM and sold 
commercially as multi-bakery shortening based on palm oil and fractions of palm oil.  It has 
been designed as an alternative to shortening due to the fact that it is non-hydrogenated and 
contains no trans-fatty acids.  Melting point is reported to be between 37-41oC and is composed 
of 49.9% of saturated fatty acids, 40.1% mono-unsaturated, and 9.6% polyunsaturated 
according to manufacturer spec sheet.  
 
Omega Pure (OP) 
HSN 
Served as the fish oil portion of the fish oil phase.  Derived from menhaden fish. Composed of 
32% unsaturated fatty acids, 24% mono-unsaturated, 36.74% polyunsaturated (35.66% omega-
3) and 7.12% that is not defined on the sheet.  EPA + DHA composed 26.12% of total fatty acid 
composition.  Also contains tocopherols to serve as antioxidants. 
Table 8 - Ingredients For Emulsion Formulations 
All of the above ingredients were necessary to prepare a stable emulsion.  Emulsions A and B differed only in the 
amount of SanTransTM 39 and OP HSN. 
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Figure 13 – Treatment Preparation Diagram 
Emulsion A and B both differed in the amount of SansTransTM 39 (palm oil) and OP HSN (fish oil) present.  Both oils 
were mixed together plus the DATEM emulsifier to make the oil phase.  The oil phase was mixed with the aqueous 
gum arabic solution to create the primary emulsion.  The primary emulsion was then mixed with the aqueous sodium 
caseinate resulting in the final (secondary) emulsion.  6g of the secondary emulsion or control was added to the 
beverage.  
 
 
 
To prepare the oil phase, both solid SansTransTM 39 (palm oil source) and liquid 
OP HSN (fish oil source) were heated in separate beakers on the same heating plate 
(Corning PC-420D) to 44oC.  The temperature of the oil mixture was monitored using a 
standard thermometer.  A temperature of 44oC was sufficient to completely melt the 
SansTransTM 39 and ensured that mixing of both oils would be uniform.  Both oils were 
combined with a proprietary quantity of rosemary antioxidant and Panodan emulsifier to 
create the oil phase.  Due to confidentiality agreements with Omega PureTM, the exact 
quantity of rosemary extract is unknown.  Panodan, in liquid form, was added to the 
mixture using a 5mL pipette.  The solution was mixed with a stir bar at a speed of 500 
rpm.   
SansTransTM 39 + 
OP HSN 
+ 
PANADAN 
(Emulsifier)
WATER 
+
GUM ARABIC
WATER 
+
Na CASEINATE
PRIMARY 
EMULSION
SECONDARY
EMULSION
MIXMIX
Na Caseinate coat BEVERAGE
6g of Emulsion 
or Control
Emulsion A and B Preparation Diagram
Prepared by Omega PureTM
 67 
 
To prepare the water phase, two equivalent water solutions were prepared: one 
that contained dissolved gum arabic and one that contained dissolved sodium caseinate.  
The gum arabic and sodium caseinate were dissolved in distilled water via stir bar 
mixing at a speed of 500 rpm in separate beakers and mixing plates at room temperature.   
Using an Ultra Turrax T 50 Basic shearing mixer (IKA WerkeTM Wilmington, 
NC) the oil phase solution was slowly added to the gum arabic water solution.  The 
shearing speed was gradually increased to maximum as the dispersion became more 
evenly mixed.  After this step, the range of the size of the oil droplets was approximately 
1-10 m. Once the dispersion was sufficiently mixed it was then passed through a 
homogenizer (Niro SoaviTM NS10011 2K Bedford, NH) at 50 Bar to break up larger oil 
droplets and then passed again at 400 Bar to further decrease the oil droplet size down to 
0.2–2 m with some flocculation.  The resulting dispersion was referred to as the 
primary emulsion as shown in Figure 13. 
Using the Turrax mixer the primary emulsion was gradually added to the sodium 
caseinate solution where the negatively charged caseinate functioned as an emulsion 
stabilizer.  Sodium caseinate can stabilize emulsions by lowering the interfacial tension 
due to its adsorption at the interface.  Similar to the first step the shearing speed of the 
Turrax mixer was gradually increased as the dispersion became more uniform.  The 
resulting dispersion was then passed through a homogenizer at 400 Bar to ensure a 
consistent oil droplet size range of 0.2–2 m with minimal flocculation.  The emulsions 
were examined under a microscope to ensure minimal flocculation and consistent droplet 
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size.  The emulsions were sealed and refrigerated at 40C until it was time to for them to 
be supplemented with the beverage as shown in Figure 13. 
 
Subjective Test - Triangle Test  
To perform the triangle test, three different groups of subjects were recruited 
from Texas A&M University using mass emails sent out to the Department of Nutrition 
and Food Science.  All subjects were college students of ages 18-25.  Group one had 22 
subjects and compared treatment A to the milkfat control treatment.  Group two also had 
22 subjects and compared treatment B to the control treatment, while group three had 19 
subjects and compared the treatment A to treatment B.  The triangle test was 
administered in the sensory lab located in the Centeq building at Texas A&M 
University.  The sensory lab contained four booths with each booth being separated by a 
divider to minimize subject interaction.  The treatment samples were prepared in a 
kitchen adjoining the sensory lab.  Each subject was assigned a booth and was instructed 
to not interact with any other subjects to avoid influencing the results.  Each subject was 
provided three treatment samples in a randomized order on a plastic food tray.  Each 
treatment sample was identified with random three digit numbers to minimize selection 
bias.  The different treatment sample was randomized for each subject.  The treatment 
samples were delivered to each subject via flip door pass-through located in the wall that 
separates the kitchen and sensory lab.  Two beverage samples supplemented with the 
milk fat control and one with either emulsion A or emulsion B were arranged on the 
food tray as shown in Figure 14. 
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Figure 14 - Layout of Triangle Test Samples on a Food Tray 
Subjects were instructed to consume samples on the food tray from left to right and then asked to identify which one 
of the three treatment samples was different. The numbers shown above are examples of randomly generated numbers. 
 
 
 
The subjects were instructed to taste each sample identified with a randomly 
generated number left to right and then asked to identify which sample was different.  
An example scorecard is shown in Figure 15.   
 
 
Figure 15 – Example Scorecard for Triangle Test 
Subjects were asked to circle the different sample on the scorecard. All subjects were screened before each test.  Part 1 
refers to the screen and Part 2 refers to the test between treatments 
 
 
The entire test consisted of two separate parts: a screen referred to as Part 1 and 
the actual treatment comparison referred to as Part 2.  The screening consisted of 
performing a triangle test by giving the subjects two HEB brand lowfat milk samples 
and one HEB brand skim milk sample supplemented with fish oil and asking the subjects 
to identify which sample was different.  After the screen, subjects were given saltine 
crackers and water to cleanse the palate for five minutes before proceeding to perform 
885
357 634
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the treatment triangle test.  Subjects that failed the screen were excluded from 
participating in the treatment triangle test.  The test involved three different groups of 
subjects.  Level of significance was set at 0.05. 
 
Subjective Test – Affective/Acceptance Tests  
The method for the affective test was adapted from a previously described 
method [162].  Ten different subjects were recruited for the affective/acceptance test 
from Texas A&M University using mass emails sent out to the Department of Nutrition 
and Food Science and The Department of Health and Kinesiology.  All subjects were 
college students ages 18-30.  Each subject was screened using the same triangle test in 
the previous section.  The test took place in the Exercise and Sports Nutrition Laboratory 
(ESNL) at Texas A&M University and required three separate visits from each subject.  
Subjects were assigned a specific study day and were required to arrive on that same day 
for each treatment for three weeks.  All subjects were provided each treatment, which 
consisted of 200 grams of the beverage mixed with six grams of one of the emulsions or 
control.  All three treatments were consumed by each subject in a randomized order.  
Post-treatment consumption, subjects were asked to assess the sensory attributes of each 
treatment’s “pleasantness,” “smell,” “visual appeal,” and “taste.”  The pleasantness 
attribute refers to the overall desirability of each treatment.  The smell attribute refers to 
how desirable the subjects found the smell of each treatment.  The visual appeal refers to 
how desirable the subjects found the appearance of each treatment.  The taste attribute 
refers to how desirable the subjects found the taste/flavor of each treatment. 10cm lines 
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were anchored left to right by the statements in a left to right order “Not 
pleasant/Pleasant,” “Visually appealing/Visually unappealing,” “Not pleasant/Pleasant,” 
and “Horrible/Fantastic”.  See Figure 16 for a visual representation of the scorecard.   
 
 
Figure 16 - Scorecard for Rating Sensory Attributes of Treatments 
Subjects (n=10) were required to fill out the beverage scorecard immediately post-beverage consumption. Subjects 
marked their rating on each line.  Subjects marked their rating of each attribute on any part of the line.  
 
 
 
Treatment Storage for the Objective Tests 
 Prior to each of the objective analyses, the treatments were stored at 4oC and 
each sample was allowed to reach a temperature of 15oC before each experiment to 
ensure consistency.  Three samples of each treatment were prepared and three readings 
were recorded for each sample for a total of nine readings for each experiment per day.  
For measuring the viscosity, nine readings were taken at each rotational speed.   
BEVERAGE SCORECARD   
1.  Pleasantness 
Not pleasant 
 
Very pleasant 
 
2.  Visual Appeal 
Visually unappealing 
 
Visually appealing 
 
3.  Smell 
Not pleasant 
 
Pleasant 
 
4.  Taste 
Horrible 
 
Fantastic 
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Objective Test – Viscosity Analysis of Treatments 
The viscosities of each treatment were measured using a rotational viscometer 
(Cole-Parmer 98936-00 Vernon Hills, IL), which measures the torque required to rotate 
a rod in a fluid at a known speed (rpm).  The torque required to turn an object in a fluid 
is a function of the viscosity of that fluid.  Viscosity was measured in centipoise (cp) as a 
function of rotational speed.  The rotation speeds were set at 1.5 rpm, 3 rpm, 6 rpm, 12 
rpm, 30 rpm, and 60 rpm.  Treatment samples were shaken for one minute prior to 
reading to ensure sample uniformity. 
 
Objective Test -pH Analysis of Treatments 
The pH of each treatment was analyzed using a pH meter (Accumet Waltham, 
MA).  The pH meter was calibrated each day before reading the first sample.  Each 
treatment was measured daily over a four day period.   The pH meter measuring probe 
was placed in each treatment sample and then the pH was displayed.   
 
Objective Test - Hunter L, a, b Color Analysis 
The Hunter L, a, b color of each treatment was measured using a colorimeter 
(Hunter D25 NC Reston, VA).  Prior to Hunter L, a, b color measurements each 
treatment sample was allowed to reach a temperature of 15oC to ensure consistency.  
Each treatment sample was analyzed and the L, a, b, values were recorded.   
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Statistical Analysis 
 The objective (pH, color and viscosity) and affective/acceptance tests results 
were analyzed using a one way analysis of variance (ANOVA).  For the triangle test, the 
null hypothesis of “no difference between samples” was rejected if at least eleven 
subjects correctly selected the different treatment using the students t-chart for reference.  
The level of significance was set at 0.05 for all tests. 
 
RESULTS 
Subjective Test – Triangle Test Results 
The triangle test demonstrated that there was no detectable sensory difference 
between each emulsion treatment compared to milkfat control (Table 9).  In each 
triangle test less than eleven subjects correctly identified the different treatment meaning 
that there was a failure to reject the null hypothesis of no difference.   
 
 Treatments Compared Number of Subjects Number 
Correct 
Reject H0 = No Difference 
(=0.05) 
Group 
One 
Control 
Treatment A 
22 5 No 
Group 
Two 
Control 
Treatment B 
22 8 No 
Group 
Three 
Treatment A 
Treatment B 
19 4 No 
Table 9 – Treatment Triangle Test Results 
When comparing the treatments the second treatment listed was the different sample 
 
 
 
Subjective Test – Affective/Acceptance Tests Results 
For each treatment, subjects reported no significant rating differences among 
pleasantness, visual appeal, smell and taste attributes.  Each attribute was rated on a 1-10 
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scale.  Any attribute rating greater than 5 was considered favorable [162].  The mean 
scorecard rating of each attribute for each treatment is summarized in Table 10. 
 
Mean Scorecard Ratings ± SD (n=10) 
 Pleasantness Visual Appeal Smell Taste 
Control 7.0  ± 2.3 6.7 ± 2.5 7.9 ± 1.4 6.9 ± 2.8 
Treatment A 6.4  ± 2.4 5.9 ± 2.5 7.3 ± 1.5 6.1 ± 2.9 
Treatment C 6.9 ± 2.4 6.0 ± 2.7 7.9 ± 1.4 6.8 ± 3.1 
Table 10 - Mean Treatment Sensory Attribute Ratings 
On a scorecard, ten subjects rated each sensory attribute on a 1-10 scale post-treatment consumption.  Any rating 
greater than 5 was considered favorable.   
 
 
 
There was not a significant difference in the mean ratings of each sensory 
attribute for each treatment.  Subjects tended to rate the pleasantness at 7.0 for the 
control treatment, 6.4 for treatment A and 6.9 for treatment B indicating that the subjects 
found each treatment to be more pleasant than not pleasant.  The mean visual appeal was 
rated at 6.7 for the control, 5.9 for treatment A and 6.0 for treatment B indicating that the 
subjects found each treatment to be visually appealing.  The mean smell was rated at 7.9 
for the control treatment, 7.3 for treatment A and 7.9 for treatment B indicating that the 
subjects found each treatment to have a more pleasant than an unpleasant smell. The 
mean taste was rated at 7.9 for the control treatment, 7.3 for treatment A and 7.9 for 
treatment B indicating that the subjects found each treatment to have a more “fantastic” 
taste (Figure 17).   It should be noted that Treatment A had the lowest mean rating for 
each sensory attribute although the difference was not significant. 
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Figure 17 – Treatment Sensory Attribute Means Across Treatments 
There were no significant differences compared to control for either treatment according to subjects (n=10) 
The error bars represent the standard deviation. 
 
 
Objective Test – Treatment Viscosity Analysis Results 
Viscosity was measured in centipoise (cp) as a function of rotational speed.  The 
rotational speeds on the viscometer were set at 1.5 rpm, 3 rpm, 6 rpm, 12 rpm, 30 rpm, 
and 60 rpm in order to characterize rheological characteristics.  Readings were taken 
each day over a four day period.   For each treatment, the viscosity was not constant and 
depended on the rotational rate of the spindle rod, which is a characteristic consistent 
with a non-Newtonian pseudoplastic.  The treatments were very viscous at 1.5 rpm 
(~6211cp) and became less viscous as the rotational rate increased.  On days 1, 2, 3 and 
4 the viscosities for each treatment did not differ significantly at any rotational speed.  
For all treatments, the viscosity decreased as the rotational rate of the spindle rod 
increased.  Bar graphs of the results are shown in Figure 18.  It should be noted that in 
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most scientific literature viscosity (y-axis) is graphed as a function of shear rate or 
rotational speed (x-axis).  The bar graph was chosen to provide a clearer visual 
distinction between the viscosities of each treatment.  
 
  
  
Figure 18 - Treatment Effect on Viscosity Over a Four Day Period 
The viscosities of each treatment did not significantly differ at each rotational speed during any of the four days of the 
four day period.  
 
 
 
Objective Test - pH Analysis of Treatments Results 
 The pH of each treatment was not significantly different nor did the pH of any 
treatment significantly change over the four day period.  The pH of each treatment 
remained at approximately 4.75, which indicates an acidic food system (Figure 19).   
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Figure 19 - pH Analysis of Treatments 
pH of each treatment was measured over a four day period. 
 
Objective Test – Comparison of Hunter L, a, b Values 
 The Hunter L, a, b, color space values of the treatments did not significantly 
differ when compared on the same day.  However, each treatment demonstrated a 
statistically significant color space change each day over a four day period (Table 11).  
The mean L value for each treatment did decrease slightly over four days which 
indicates the sample became darker. The mean a value increased over four days which 
indicates that the intensity of the red color increased for each treatment.  The mean b 
value of each treatment also significantly increased over four days indicating that the 
intensity of blue increased. 
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  Mean Hunter L, a, b Color Values ± SD (n=9) 
L a b 
Day 1 Control 50.010a ± 0.690 9.069b ± 0.109 15.423c ± 0.071 
Treatment A 50.005a ± 0.713 9.066b ± 0.117 15.395c ± 0.082 
Treatment B 49.960a ± 0.710 9.076b ± 0.117 15.395c ± 0.093 
    
Day 2 Control 49.707d ± 0.378 9.172e ± 0.042 15.884f ± 0.052 
Treatment A 49.687d ± 0.428 9.169e ± 0.055 15.863f ± 0.066 
Treatment B 49.673d ± 0.510 9.172e ± 0.052 15.841f ± 0.052 
    
Day 3 Control 48.811g ± 0.197 9.420h ± 0.065 16.189i ± 0.075 
Treatment A 48.743g ± 0.268 9.409h ± 0.059 16.162i ± 0.084 
Treatment B 48.782g ± 0.309 9.411h ± 0.050 16.159i ± 0.082 
    
Day 4 Control 49.142j ± 0.159 9.319k ± 0.023 16.110l ± 0.044 
Treatment A 49.073j ± 0.189 9.321k ± 0.034 16.116l ± 0.071 
Treatment B 48.995j ± 0.236 9.309k ± 0.045 16.124l ± 0.062 
Table 11 - Hunter L, a, b Values Measured Over Four Days 
“L” values measures light vs. dark where 0-50 indicates dark and a 51-100 indicates light.  The “a” values indicate red 
vs. green where a positive number indicates red and a negative number indicates green.  The “b” values indicate 
yellow vs. blue where a positive number indicates yellow and a negative number indicates blue.  Values with different 
letters are considered significantly different (p-value > 0.05). 
 
 
DISCUSSION 
In phase one of the study it was shown that emulsions A and B stimulated the 
secretion of the hormones PYY and GLP-1 in STC-1 cells indicating the possibility for 
the emulsions to serve as satiety inducing ingredients via activation of the of the 
intestinal feedback mechanism known as the ileal brake of which PYY and GLP-1 are 
considered biomarkers for.  Since the emulsions exhibit a stimulatory effect on PYY and 
GLP-1 secretion in STC-1 cells, there is great interest in determining if the emulsions 
when orally consumed can similarly affect ileal brake activation in human subjects.  
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The purpose of phase two was to develop a food system beverage to serve as a 
vehicle for the emulsions.  The beverage was supplemented with either milkfat control 
or emulsion A or Emulsion B and were referred to as the control treatment, treatment A 
and treatment B.  The results demonstrated that our beverage is able to mask any 
sensory, flavor, color, pH and rheological differences of each treatment with the only 
ingredient being different are the emulsions.  Therefore the beverage has the potential to 
serve as vehicle for the emulsions in a satiety study with humans.  This is important 
because any significant sensory differences between treatments could potentially 
influence satiety in human volunteers.    
For the triangle test, 22 subjects were asked to choose between treatment A and 
two control treatments. The subjects correctly selected treatment A only five times.  
When comparing treatment B to control only five subjects correctly selected treatment 
B.  When comparing treatment A to treatment B, only four out of nineteen subjects 
correctly chose treatment B which served as the different sample.  The results indicate 
that each treatment does not significantly exhibit an overall sensory difference.   
For the affective/acceptance tests, subjects were asked to rate the sensory 
attributes of pleasantness, visual appeal, smell and taste for each treatment.  Each subject 
consumed all three treatments one week apart in a randomized treatment order.  Subjects 
did not report a significant difference between pleasantness, visual appeal, smell and 
taste for each treatment.  Subjects rated the mean pleasantness of the beverage at 6.8, 
while the mean visual appeal was rated at 6.2, the mean smell was rated at 7.7, and mean 
the taste was rated at 6.6 indicating that overall the subjects found each attribute to be 
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more desirable than undesirable since the mean ratings of each attribute did not fall place 
5 indicating that all three treatments were equally liked.  
All of the objective test results showed that there was no significant difference 
among treatments, which was consistent with the subjective test results.  Treatment 
viscosities did not significantly differ at the 1.5 rpm, 3 rpm, 6 rpm, 12 rpm, 30 rpm, and 
60 rpm rotational speeds on any of the four test days.  However, the viscosities of each 
treatment did significantly change over the four day period.  The treatments display 
rheopectic, followed by thixotropic characteristics since the viscosity increases and then 
decreases over time at a constant shear rate.  From day 1 to day 2 each treatment 
exhibited rheopectic characteristics since there was a significant increase in viscosity at 
all rotational speeds.  From day 2 to day 3 and day 3 to day 4 each treatment exhibited 
thixotropic characteristics where the viscosities decreased at all rotational speeds.  On 
each day, the treatment viscosities non-linearly decreased as the rotational speed of the 
spindle increased, a process known as shear thinning.  Shear thinning is a defining 
characteristic of a non-Newtonian pseudoplastic beverage, which is consistent with 
previous studies using smoothies [181, 182].  These changes in viscosity are likely 
caused by inactivation of the fruit enzymes as well as other components that influence 
viscosity, which can affect the shelf life.  It was previously shown that satiety was higher 
in subjects that consumed a high viscosity (29500 cp) beverage described as “barely 
pourable” compared to a low viscosity (60cp) beverage described as “watery” [190].   
Another study that examined the effect of viscosity on satiety and reported that a fruit 
smoothie that contained fresh mango, peach and papaya fruit juice with tara gum that 
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had an estimated viscosity range of 800 cp – 3800 cp increased satiety [189].   The 
viscosity of each treatment in this study falls within this range, although the main 
components of the beverage that contributed to the texture were the yogurt, milk, 
bananas and strawberries.  
 Unlike color or viscosity, the pH for each treatment did not significantly change 
over the course of four days and remained at approximately 4.75.  The main ingredients 
contributing to the pH were likely the yogurt and the strawberries.  Yogurt and 
strawberry have acidic pHs between 3.0 - 4.0, while milk has a pH at around 6.6.  
Maintaining a stable pH is an important characteristic of a stable food system since an 
unstable pH can affect the flavor, color and texture.   An acidic pH can lead to a sour 
flavor due to protonation of weak acids.  pH can also affect the texture and viscosity 
since the proteins such as casein will precipitate and coagulate if the pH decreases below 
the isoelectric point.  The pH can also affect pigment molecules leading to color 
changes.  All of the aforementioned qualities can negatively affect food system quality.  
However in all treatments, pH variation or fluctuation was not an issue. 
 Hunter L, a, b color values for each treatment did not significantly differ on any 
of the four test days.  However, the Hunter L, a, b colors of each treatment did 
significantly change over the four day period.  The brownish dominant color of each 
treatment was still present on Day 1 and Day 4. On Day 4 the beverage had undergone 
noticeable water separation as shown in the right picture of Figure 20. 
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Day 1 Day 5 
Figure 20 – Treatment Texture Changes Over a Five Day Period 
On Day 1, the beverage had a uniform appearance.  By Day 4, the beverage had undergone noticeable water 
separation.  There was not a noticeable difference in separation between treatments.  It is important to note that the 
photographs inadvertently altered the color appearance due to lighting variations on different days. The actual color 
difference of the beverages was not pronounced, both being chocolate brown. The photographs were not intended to 
show color changes, but rather to emphasize the beverage emulsion stability change over time. 
 
 
In this phase of the research it was demonstrated that the treatments are 
objectively and subjectively indistinguishable from one another.  In addition to the 
emulsions, the beverage also contains several other ingredients that can potentially 
influence satiety or emulsion stability.    
However, the beverage has some limitations in regards to shelf life.  Appearance, 
texture and color all significantly changed over the course of four days.  The treatments 
displayed water separation after five days and a statistically significant color change 
over the same time frame, potentially affecting palatability and the beverage’s ability to 
properly mask the emulsion differences.  Due to lack of time and funding, trained 
panelists could not be recruited to define a flavor profile for the beverage and determine 
how those flavors might be affected by the addition of the emulsions or how the flavors 
would change over the course of several days.  Several researchers observed that the 
banana and strawberry flavors were the dominate flavors on day 1, but on day 2, the 
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chocolate flavor became more dominant and by day 3 the banana and strawberry flavors 
were not present.  Despite these limitations, it has been demonstrated that the treatments 
are objectively and subjectively indistinguishable from one another and are therefore 
viable to test the effects of the treatments on satiety in human subjects.   
To reiterate, in phase one it was shown that emulsions A and B stimulated the 
secretion of the ileal brake biomarkers, GLP- and PYY in STC-1 cells.  In this phase it 
was demonstrated that the formulated beverage was capable of serving as vehicle for the 
emulsions.  Therefore, the next phase of the study is to determine if the emulsion 
treatments could influence feelings of satiety, energy intake and the expression of ileal 
brake hormones, GLP-1, PYY, ghrelin and leptin in human subjects.  All of which were 
necessary to determine whether the emulsion treatments had the potential to serve as an 
option for individuals concerned with weight management. 
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CHAPTER IV 
FISH OIL EMULSIONS AND THEIR EFFECTS ON SATIETY ON HUMAN 
SUBJECTS
BACKGROUND AND RATIONALE 
In phase one of this research it was demonstrated that two emulsions referred to 
as emulsion A and emulsion B composed of different ratios of palm and fish oil induced 
the secretion of the hormones GLP-1 and PYY from STC-1 cells.  In the second phase, a 
fruit and dairy blended beverage was formulated to serve as a vehicle for the emulsions. 
The beverage was formulated such that there were no statistically significant objective or 
subjective differences between the beverage supplemented with emulsion A or emulsion 
B compared to control.  The objective tests compared the viscosities, pH and color of 
each treatment.  For the subjective sensory tests, triangle tests and affective tests were 
administered and demonstrated no significant difference between treatments.  Therefore 
there is an interest in determining if the emulsion treatments may exhibit effects on 
satiety and energy intake individuals. 
Obesity, which is defined as abnormal or excessive fat accumulation that may 
impair health has emerged as a very serious threat to the world health population and has 
continued on an upward trend since the mid-1980s.  As of August 2014, the World 
Health Organization recently reported the following: worldwide obesity has nearly 
doubled since 1980; in 2008, more than 1.4 billion adults, 20 and older, were 
overweight, of which over 200 million men and nearly 300 million women were obese; 
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35% of adults aged 20 and over were overweight in 2008, and 11% were obese; 65% of 
the world's population live in countries where overweight and obesity kills more people 
than underweight; more than 40 million children under the age of 5 were overweight or 
obese in 2012 [1].  Energy restriction is most commonly used to counter obesity, but a 
better solution may lie in the manipulation of macronutrient composition of diets to 
fortify foods or beverages with macromolecules, such as protein, fats or emulsions that 
exploit various biological mechanisms that regulate energy intake.  One such biological 
feedback mechanism is the ileal brake.   
The ileal brake is the primary inhibitory feedback mechanism that controls the 
transit of food through the GI tract.  Ileal brake activation results in a delay in gastric 
emptying leading to an increase in small intestine transit time for both solid and liquid 
food [70, 125, 126].  Dietary fats that have been hydrolyzed into FFA form are 
considered the most potent activators of the ileal brake and have been confirmed by 
many studies [70, 128-134].   However, a recent proof-of-concept study involving 
normal weight individuals investigated the effect of ileal infusion of sucrose and casein 
on food intake, release of CCK, GLP-1 and PYY, gastric emptying rate and small-bowel 
transit time.  They demonstrated that the ileal brake-satiating effect leading to a 
significant decrease in food intake is also demonstrated by proteins and carbohydrates 
[143].  The hormones, GLP-1 and Peptide-YY (PYY) are secreted from the intestinal L-
calls into circulation upon nutrient stimulation and are considered biomarkers of the ileal 
brake and satiety.   
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GLP‑1, an incretin, is one of several cleavage products of the proglucagon gene.  
It is produced in the intestinal L-cells located along the mucosa of the ileum and the 
proximal colon that is secreted into circulation upon nutrient stimulation.  GLP‑1 
enhances glucose-dependent insulin secretion, inhibits glucagon release from the 
pancreatic -cells and delays nutrient absorption through inhibition of gastric emptying 
and intestinal motility [38-41].  GLP-1 exhibits rapid and prolonged effects in response 
to nutrient digestion post-meal consumption [49-51].  Once in circulation, GLP-1 has a 
short half-life of ~1-2 minutes due to rapid degradation by the DPP-4 [52-66].  Once 
GLP-1 crosses the blood brain barrier, it will bind to receptors in the hypothalamic 
arcuate nuclei, promoting appetite suppression [48, 67].  
PYY, like GLP-1, is a satiety hormone that is secreted by intestinal L-cells and 
serves as an inhibitor of pancreatic exocrine secretion and intestinal motility [70].   Once 
in circulation, PYY is degraded by DPP-4 into its active PYY3-36 form.  PYY3-36 is able 
to exclusively bind to the Y2 receptor in the hypothalamic arcuate nucleus. Once bound 
to the Y2 receptor PYY3-36 suppresses the expression of the prohunger hormone 
neuropeptide Y (NPY) [72-75].  It is important to note that in a study examining 
individuals who underwent gastric bypass surgery, that PYY and GLP-1 plasma levels 
were significantly elevated and has been suggested that this is a possible factor in 
weightloss post-surgery [76].   
Leptin is a satiety hormone that is secreted from white adipose tissue in response 
to food consumption, but is not considered to be a biomarker for the ileal brake.  Once in 
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the blood stream leptin crosses the blood brain barrier where it will bind to leptin 
receptors in hypothalamic arcuate nucleus to promote appetite suppression [77-82]. 
Unlike GLP-1, PYY, and leptin, ghrelin is an appetite-stimulating hormone that 
is produced by the P/D1 cells that line the fundus of the stomach [84].  Ghrelin plasma 
levels elevate during fasting and decreases post meal consumption in normal individuals.  
Once ghrelin crosses the blood-brain barrier it binds to ghrelin receptors in hypothalamic 
arcuate nucleus inducing the expression of NPY increasing appetite [85, 86].   
It is important to note that most of the studies examining whether certain 
macronutrients could activate the ileal brake were performed via ileal infusion, which is 
not practical for common weight management [70, 128-134].  As such, dietary activation 
of the ileal brake poses a greater challenge.  Therefore, there is great interest in fortifying 
food products with lipid delivery systems, such as emulsions, which inhibit lipid 
digestion such that lipid exposure to the ileum is increased, potentially activating the 
ileal brake.   
An emulsion is a mixture of two immiscible liquids in which one liquid is 
dispersed (dispersed phase) in the other (continuous phase).  This mixture is stabilized 
by an emulsifier, a molecule containing a hydrophilic group that interacts with the water 
phase, and the hydrophobic group that interacts with the oil phase.  The simplest 
emulsions are classified as oil in water (O/W) or water in oil (W/O).   
The commercial product OlibraTM (Lipid Technologies Provider AB (LTPAB), 
Karishamn, Sweden) is an emulsion composed of a 95:5 ratio of palm oil to oat oil in 
which the galactolipids derived from oat oil serve as the emulsifier.  OlibraTM when 
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consumed with yogurt has been previously shown to suppress appetite and reduce food 
intake in human subjects [149-151].   
There have been numerous studies that have examined the effects of OlibraTM on 
appetite suppression, energy intake and potential ileal brake activation.  The earliest 
known study examined the effects of OlibraTM added to yogurt (OlibraTM treatment) on 
energy and macronutrient intake in only non-obese subjects (BMI < 30).  It was found 
that mean energy intakes were significantly lower after consumption of the OlibraTM 
treatment compared with the milkfat control treatment [150].  These results were 
consistent with a later study that also included non-overweight (BMI 20-24.9 kg/m2), 
overweight (BMI 25-29.9 kg/m2) and obese (BMI > 30 kg/m2) subjects and found that 
mean energy intakes were significantly lower for the OlibraTM treatment compared with 
the control in non-overweight and overweight subjects, but not obese subjects [149].   
Another study by the same group examined whether there effects of OlibraTM were dose-
dependent using non-overweight subjects (BMI 20-24.9 kg/m2) and reported that mean 
energy intakes were progressively reduced with increasing doses of OlibraTM treatment. 
The authors suggested that OlibraTM exerted it’s effects via the ileal brake [151].   
Another study examined whether consumption of the OlibraTM treatment had an effect 
on orocecal transit time (OCTT) by following blood sulfapyridine levels, a metabolite of 
salazopyrine in the colon.  Orally consumed salazopyrine serves as a marker for OCTT 
since it is poorly absorbed in the gastrointestinal tract, but is rapidly absorbed in the 
colon upon being hydrolyzed by microflora.  The results showed that there was a 
statistically significant delay in the emergence of sulfapyridine in serum after 
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consumption of the OlibraTM treatment versus milkfat control treatment. This resulted in 
a greater OCTT due to fat emulsion consumption and provided the strongest evidence 
that OlibraTM was exerting its effects via ileal brake activation [170].  The most 
comprehensive study on the OlibraTM treatment assessed its effects on weight 
maintenance after weight loss including effects on body composition, resting energy 
expenditure, fat oxidation, reported appetite, and satiety hormones analysis.  Their 
findings indicated that consumption of the OlibraTM treatment resulted in a significant 
decrease in body composition, significantly greater resting energy expenditure, 
significantly greater fat oxidation, significantly decreased appetite and greater satiety 
hormone expression results compared to the milkfat control treatment [167].  However, 
the findings of later studies were not consistent with these [168, 169].  It is important to 
note that OlibraTM reportedly only exhibits its effects when consumed with yogurt [171].   
A few studies have investigate the effects of other emulsion treatments.  One 
such case involves a Korean pine nut oil emulsion (PinnothinTM) which exhibited similar 
effects on satiety and energy intake as OlibraTM [191-193].  Taken together there is 
sufficient evidence that demonstrates the potential of utilizing emulsions as satiety 
inducing agents. 
For our specific study, two oil in water emulsions that differed in their palm oil 
to fish oil ratios, being either 2:1 (A) or 1:1 (B) were prepared by Omega Protein 
(Houston Texas).  Omega Protein had an interest in developing their own emulsion to 
serve as a marketable alternative to OlibraTM.  Palm oil does possesses high amounts of 
palmitic acid (~44%) and oleic acid (~37%) both of which had been shown to have 
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potential in activation of the ileal brake [138, 139].  In addition to the benefits provided 
by palm oil, fish oil has several properties that suggest it could serve as a potential 
activator of the ileal brake.  First, over 80% of fish oil is comprised of long chain fatty 
acids, which have been demonstrated to delay gastric emptying [138, 139].  Second, fish 
oil also contains a high amount of unsaturated fatty acids (55%) which some studies 
suggest that a higher degree of unsaturation corresponds to a greater effect on satiety, 
although it is not conclusive [140-142].  In addition to the potential effect on satiety, the 
omega-3 (n-3) fatty acids specifically docosahexaenoic acid (DHA-22:6n-3) and 
eicosapentaenoic acid (EPA-20:5n-3) are considered anti-inflammatory nutrients and 
have been often been used a dietary supplement for inflammatory diseases such as 
rheumatoid arthritis and cardiovascular disease [174].  Figure 21 illustrates the 
emulsions potential mechanism of action.  Phase three tested the hypothesis that the 
treatments induced satiety, reduced energy intake and induced a satiety hormone 
response in human subjects.   
 
Figure 21 - Proposed Mechanism of Action of Emulsions 
OlibraTM and the emulsions have different fatty acid profiles.  Fatty acids that reach the ileum intact have the potential 
to activate the ileal brake.  This will induce the release of satiety hormones into circulation. 
Stomach
Duodenum
Jejunum
Ileum
Colon
Adipose tissue
Brain
(hypothalamus)
Feeding center(+) = appetite stimulant
(-) = appetite suppressant
Ghrelin (+)
GLP-1 (-) PYY (-) 
Leptin (-) 
Fatty Acid OlibraTM Emulsion A Emulsion B
Myristic 14:0 0.95 3.79 5.10
Palmitic 16:0 42.23 35.24 31.35
Palmitoleic 16:1 0.00 4.28 6.30
Stearic 18:0 4.19 3.99 3.85
Oleic 18:1 36.57 28.17 24.20
Linoleic 18:2 10.70 6.65 5.50
Linolenic 18:3 0.10 0.51 0.75
Arachidonic 20:4 0.00 0.54 0.80
EPA 20:5 0.00 4.93 7.25
DHA 22:6 0.00 4.01 5.90
Other -- 5.28 7.88 9.00
Fatty Acid Profile of OlibraTM and Emulsion Treatments
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SUBJECTS AND METHODS 
Subject Recruitment 
Ten subjects, consisting of eight females and two males were recruited for the 
study using posted advertisements and mass emails sent out to the Department of 
Nutrition and Food Science and The Department of Health and Kinesiology at Texas 
A&M University.  The subjects had a mean age of 21.8 years, a mean height of 165.1 
cm, a mean weight of 73kg, and a mean BMI of 26.8.  Subjects were non-smoking, non-
dieting, not pregnant, and not taking any prescribed medication.  All subjects indicated a 
preference for cheese pizza as the satiety lunch.  All subjects signed consent forms 
before participating in the study.  The study was approved by the Texas A&M 
University IRB. 
 
Study Design 
The study was conducted in the Exercise and Sports Nutrition Laboratory 
(ESNL) at Texas A&M University.  The study was a randomized placebo controlled 
single-blinded crossover trial that involved testing the effects of three treatments on 
satiety and energy consumption.  Each subject picked a day of the week, excluding 
Saturday and Sunday, as their day of study and were required to arrive on that same day 
for each treatment for three consecutive weeks.  The order that each subject received 
each of the three treatments was randomized.  For each study day, subjects were 
instructed to arrive fasted for 12 hours, arrive at 8:45am to have the baseline blood 
sample collected and complete a baseline VAS satiety scorecard.  After the baseline 
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blood collection at 9:00am, subjects were instructed to consume the treatment beverage 
within five minutes.  Additional blood samples were collected at 30, 90 and 180 minutes.  
Subjects were also instructed to complete VAS satiety scorecards every 30 minutes until 
noon.  From arrival at the laboratory until noon, subjects were instructed not to engage in 
any strenuous physical activity nor, were they permitted to consume anything other than 
water.  At noon, subjects were provided a whole cheese pizza purchased from Little 
Caesars Pizza and instructed to eat until full.  The amount of pizza consumed by each 
subject was recorded and weighed.  Figure 22 displays the schedule for each study day. 
 
 
Figure 22 - Study Day Schedule  
Subjects (n=10) followed the above schedule for each treatment for three consecutive weeks.  Each subject received a 
different treatment each week.  The order of treatment consumption was randomized for each subject. 
 
 
 
Treatment Preparation 
Beverage ingredients excluding the emulsions were purchased from an H.E.B. 
supermarket located in College Station, Texas on a weekly basis in order to ensure 
consistency and freshness for each experiment.  The treatments were freshly prepared 
prior to each subjective and objective comparison test.  Milkfat from heavy whipping 
cream served as the control in accordance to previous studies [149-151].  Table 12 
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contains an approximate macronutrient composition from a 200 gram sample of 
beverage containing 6 grams of each emulsion or the milkfat control. 
 
(a) 
 Carbohydrates 
(g) 
Sugar 
(g) 
Fiber 
(g) 
Starch 
(g) 
Fat 
(g) 
Protein 
(g) 
Kilocalories 
Banana 14 8.74 1.38 3.68 0 0.46 50.6 
Vanilla 0 0.23 0 0 0 0 5.52 
Fat Free Vanilla 
Pudding 
1.2 0 0 1.15 0 0 4.6 
Hersheys Syrup 11 9.2 0.46 1.38 0 0.46 46 
Strawberries 1.3 0.81 0.32 0.16 0 0.161 5.15 
Skim milk 2.8 2.76 0 0 0 1.84 19.78 
Yogurt 3.5 3.45 0.23 0 0 2.53 25.3 
Total (pre-treatment) 33 25.2 2.4 6.4 0 5.5 157.0 
         
(b) 
Milkfat (control) (6g) 0 0 0 0 1.8 0.1 16.6 
Emulsion A (6g) 0 0 0 0 1.8 0.1 16.6 
Emulsion B (6g) 0 0 0 0 1.8 0.1 16.6 
Total with treatment 33 25.2 2.4 6.4 1.8 5.5 173.2 
Table 12 - Macronutrient Composition of Beverage and Emulsions 
Macronutrient composition was estimated using food nutrition labels.  (a) refers to the beverage only and (b) refers to 
the emulsions.  The Strawberry and banana composition was estimated using Dole’s nutrition website.  The control is 
composed of milkfat from heavy whipping cream. 
 
 
 
All of the ingredients were combined into a blender (Oster 14 Speed, Rye, NY) 
and set on the lowest speed (setting “stir”) for one and a half minutes.  The resulting 
treatments had a chocolate brown appearance and viscous texture (Figure 23).   
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Figure 23 – Visual Representation of Each Treatment 
The above picture was taken following beverage preparation and is intended to provide a visual representation of the 
color and viscosity. 
 
 
 
Emulsion Composition and Preparation 
The emulsions for the beverage were prepared by Omega Pure (Houston, Texas).  
Two emulsions which were referred to as A and B were tested.  The emulsions differed 
in their palm oil to fish oil ratios, being either 2:1 (A) or 1:1 (B).  Table 13 shows the 
quantities in grams of each ingredient present in a six gram sample emulsion, the amount 
added per 200g of beverage.  Table 14 presents a description of the components used to 
prepare emulsion A and emulsion B.  Figure 24 shows the treatment preparation 
diagram. 
 
Emulsion A  
2:1 palm oil: fish oil ratio  
Emulsion B  
1:1 palm oil: fish oil ratio 
Ingredient % Amt / 6g 
 
Ingredient % Amt / 6g 
Water 66.58% 4g 
 
Water 66.58% 4g 
SansTrans 39 19.58% 1.2g 
 
SansTrans 39 14.69% 0.9g 
OP HSN 9.79% 0.6g 
 
OP HSN 14.69% 0.9g 
Na-caseinate 1.96% 0.1g 
 
Na-caseinate 1.96% 0.1g 
Gum Arabic 1.37% 0.1g 
 
Gum Arabic 1.37% 0.1g 
K-sorbate 0.49% ~0g 
 
K-sorbate 0.49% ~0g 
Panodan 0.23% ~0g 
 
Panodan 0.23% ~0g 
Table 13 - Quantity of Emulsion Ingredients Present in Each Treatment 
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Ingredient Function 
Gum arabic A complex mixture of glycoproteins and polysaccharides that is used primarily in the food 
industry as a stabilizer for the purpose of reducing the surface tension of emulsions. 
 
Panadan A diacetyl tartaric acid ester of mono-diglycerides (DATEM) made from edible, refined 
soybean oil.  Served as the emulsifier to make primary emulsion.   
 
Na-caseinate Proteins derived from milk that are commonly used as food stabilizers.  Used as coating to the 
primary emulsion to form the secondary emulsion. 
 
K-sorbate Served as a preservative against molds and yeasts.  
 
SansTransTM 39 Served as the palm oil portion of the palm oil phase.  Developed by Lokers CroklaanTM and sold 
commercially as multi-bakery shortening based on palm oil and fractions of palm oil.  It has 
been designed as an alternative to shortening due to the fact that it is non-hydrogenated and 
contains no trans-fatty acids.  Melting point is reported to be between 37-41oC and is composed 
of 49.9% of saturated fatty acids, 40.1% mono-unsaturated, and 9.6% polyunsaturated 
according to manufacturer spec sheet.  
 
Omega Pure (OP) 
HSN 
Served as the fish oil portion of the fish oil phase.  Derived from menhaden fish. Composed of 
32% unsaturated fatty acids, 24% mono-unsaturated, 36.74% polyunsaturated (35.66% omega-
3) and 7.12% that is not defined on the sheet.  EPA + DHA composed 26.12% of total fatty acid 
composition.  Also contains tocopherols to serve as antioxidants. 
Table 14 - Ingredients For Emulsion Formulations 
All of the above ingredients were necessary to prepare a stable emulsion.  Emulsions A and B differed only in the 
amount of SanTransTM 39 and OP HSN. 
 
 
 
 
Figure 24 – Treatment Preparation Diagram 
Emulsion A and B both differed in the amount of SansTransTM 39 (palm oil) and OP HSN (fish oil) present.  Both oils 
were mixed together plus the DATEM emulsifier to make the oil phase.  The oil phase was mixed with the aqueous 
gum arabic solution to create the primary emulsion.  The primary emulsion was then mixed with the aqueous sodium 
caseinate resulting in the final (secondary) emulsion.  6g of the secondary emulsion or control was added to the 
beverage.  
SansTransTM 39 + 
OP HSN 
+ 
PANADAN 
(Emulsifier)
WATER 
+
GUM ARABIC
WATER 
+
Na CASEINATE
PRIMARY 
EMULSION
SECONDARY
EMULSION
MIXMIX
Na Caseinate coat BEVERAGE
6g of Emulsion 
or Control
Emulsion A and B Preparation Diagram
Prepared by Omega PureTM
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To prepare the oil phase, both solid SansTransTM 39 (palm oil source) and liquid 
OP HSN (fish oil source) were heated in separate beakers on the same heating plate 
(Corning PC-420D) to 44oC.  The temperature of the oil mixture was monitored using a 
standard thermometer.  A temperature of 44oC was sufficient to completely melt the 
SansTransTM 39 and ensured that mixing of both oils would be uniform.  Both oils were 
combined with a proprietary quantity of rosemary antioxidant and Panodan emulsifier to 
create the oil phase.  Due to confidentiality agreements with Omega PureTM, the exact 
quantity of rosemary extract is unknown.  Panodan, in liquid form, was added to the 
mixture using a 5mL pipette.  The solution was mixed with a stir bar at a speed of 500 
rpm.   
To prepare the water phase, two equivalent water solutions were prepared: one 
that contained dissolved gum arabic and one that contained dissolved sodium caseinate.  
The gum arabic and sodium caseinate were dissolved in distilled water via stir bar 
mixing at a speed of 500 rpm in separate beakers and mixing plates at room temperature.   
Using an Ultra Turrax T 50 Basic shearing mixer (IKA WerkeTM Wilmington, 
NC) the oil phase solution was slowly added to the gum arabic water solution.  The 
shearing speed was gradually increased to maximum as the dispersion became more 
evenly mixed.  After this step, the range of the size of the oil droplets was approximately 
1-10 m. Once the dispersion was sufficiently mixed it was then passed through a 
homogenizer (Niro SoaviTM NS10011 2K Bedford, NH) at 50 Bar to break up larger oil 
droplets and then passed again at 400 Bar to further decrease the oil droplet size down to 
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0.2–2 m with some flocculation.  The resulting dispersion was referred to as the 
primary emulsion as shown in Figure 23. 
Using the Turrax mixer the primary emulsion was gradually added to the sodium 
caseinate solution where the negatively charged caseinate functioned as an emulsion 
stabilizer.  Sodium caseinate can stabilize emulsions by lowering the interfacial tension 
due to its adsorption at the interface.  Similar to the first step the shearing speed of the 
Turrax mixer was gradually increased as the dispersion became more uniform.  The 
resulting dispersion was then passed through a homogenizer at 400 Bar to ensure a 
consistent oil droplet size range of 0.2–2 m with minimal flocculation.  The emulsions 
were examined under a microscope to ensure minimal flocculation and consistent droplet 
size.  The emulsions were sealed and refrigerated at 40C until it was time to for them to 
be supplemented with the beverage as shown in Figure 23. 
 
Visual Analogue Scales to Measure Satiety 
Upon arrival and prior to treatment consumption and blood collection, subjects 
rated the satiety attributes of Hunger, Satisfaction, Fullness, and Thoughts of Food 
(TOF) using VAS scorecards to obtain the baseline appetite ratings following previously 
established protocols [162-164].  Subjects completed the same scorecard at 30, 60, 90, 
120, 150, and 180 minutes.   The subjects marked an “X” on the line to indicate their 
feelings at the timed intervals above for each of the four attributes on different 10cm 
lines anchored by statements in a left to right order “I am not hungry at all/Very 
hungry,” “I am not full at all/Very full,” “I am completely empty/I can’t eat another 
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bite,” and “Nothing at all/A large amount,” as shown in Figure 25.  In reporting satiety 
via VAS, the post-baseline ratings at each timepoint were subtracted from the baseline 
and graphed as the change from baseline [162-164]. 
 
Figure 25 - Beverage Sensory Scorecard and VAS Appetite Scorecard 
Subjects were required to complete satiety scorecard pre-beverage consumption for the baseline and every 30 minutes 
during the 180 minutes post-beverage consumption prior to pizza lunch. 
 
 
 
Satiety Meal Measuring Kilocaloric Intake 
Cheese pizza was chosen as the single satiety meal food item. The pizzas were 
purchased from Little Caesars Pizza in College Station, TX.  Little Caesar’s pizza was 
chosen because of cost, convenience and was predetermined through subject/researcher 
interactions to be a preferred satiety lunch offering as a reliable method to estimate 
kilocarolic intake 180 minutes post-treatment consumption.  This is consistent with a 
previously reported study that used cheese pizza as their satiety lunch [163].  The pizzas 
were approximately 35.6 cm in diameter with eight total slices.  According to the 
SATIETY   
1.  How hungry do you feel? 
I am not hungry at all 
 
Very hungry 
 
2.  How full do you feel? 
I am not full at all 
 
Very full 
 
3.  How satisfied do you feel? 
I am completely 
empty  
I can’t eat another 
bite 
 
4.  How much do you think you can eat now? 
Nothing at all 
 
A large amount 
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nutrition facts provided by the Little Caesars website, each slice of pizza weighed 
approximately 117g and provided 250 kilocalories.  Pizzas were weighed and inspected 
prior to purchase to confirm that the totals provided were accurate. 
Following the 180 minute blood collection, subjects were instructed to eat whole 
slices of pizza until satiation.  They were instructed to not leave any crust in order to 
accurately estimate kilocalorie consumption per treatment.  In the event that the subject 
did not feel they could eat a whole slice, the slice was cut in half and kilocalories were 
estimated based on the weight.    
 
 
Blood Sample Collection 
Subjects arrived at the study laboratory before 9am and a baseline blood sample 
was collected into EDTA suction tubes using a syringe by a registered nurse or a 
certified staff member in an enclosed area of the laboratory.  Subjects were monitored by 
the ESNL staff to ensure subject comfort.  Immediately after the baseline blood 
collection, subjects were returned to the lounge area of the laboratory where they 
consumed their assigned beverage emulsion treatment for that day.  Additional blood 
samples were collected at 30, 90, and 180 minutes post-treatment consumption.  
Immediately following collection, all blood samples were centrifuged and the plasma 
was collected and then stored in a -20oC freezer in the ESNL until analysis.  
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Analysis of GLP-1, PYY, Ghrelin and Leptin Expression  
For analysis, plasma samples were thawed on ice and dipeptidyl peptidase IV 
inhibitor was added to the test tubes to prevent degradation of GLP-17-36 into the inactive 
form.  GLP-1 concentration was analyzed in its active form which consists of only 
amino acid residues 7-36.  Leptin, ghrelin, total PYY and GLP-1 were analyzed using 
the Human Metabolic Hormone Magnetic Bead Panel - Metabolism Multiplex Assay kit 
provided by EMD-Millipore (Billerica, MA) on a Luminex 200 according to 
manufacturer’s instructions. 
 
Statistical Analysis 
For each time point, mean VAS scorecard ratings and the mean hormone levels 
present in the blood samples for each treatment were compared and analyzed using a one 
way analysis of variance (ANOVA).  The level of significance was set at a p-value < 
0.05 for all experiments. 
 
RESULTS 
Analysis of VAS Scorecards Satiety Ratings  
Using VAS scorecards, each subject rated their Hunger, Satisfaction, Fullness, 
and Thoughts of Food (TOF), prior to the consumption of each treatment to serve as the 
baseline.  VAS scorecards were subsequently filled out at 30, 60, 90, 120, 150 and 180 
minutes post-treatment consumption.  The mean ratings of each satiety attribute for each 
treatment were plotted as a function of time (Figure 26). There was a decrease in hunger 
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rating for all treatments at 30 minutes with the control demonstrating the greatest 
decrease, but was not significantly different from treatment A or B (Figure 26A).  For 
satisfaction rating there was not a significant difference between the treatments, but 
treatment B demonstrated the greatest satisfaction rating up to 120 minutes post-
treatment consumption (Figure 26B).  For fullness rating, there was not any significant 
nor any noteworthy differences between treatments (Figure 26C).  For TOF rating, there 
were no significant differences among treatments, although treatment B demonstrated 
the smallest decrease at 60 and 90 minutes, but treatment B also demonstrated the 
greatest TOF rating increase after 90 minutes, which persisted until 180 minutes (Figure 
26D).   
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(a) (b) 
  
(c) (d) 
 
Figure 26 - Mean Satiety VAS Ratings for Treatments 
The effect on each satiety attribute response from the VAS scorecards of each treatment presented as change from 
baseline scores were graphed as function of time. Data at each time point is means ± SEM (n = 10).  The title of each 
graph corresponds to the question presented to each subject on the VAS scorecard shown in Figure 25. 
 
 
 
Kilocaloric Intake of Satiety Lunch  
At minute 180 and completion of their blood draw, subjects were provided one 
whole cheese pizza and were instructed to eat at a normal pace on each treatment day.  
In all instances, subjects reached satiation within 30 minutes and there was not a single 
instance of a subject eating more or wanting to eat more than one whole pizza.  Subjects 
who were provided the control treatment consumed between 3 - 8 slices of cheese pizza, 
2 - 6.66 slices for treatment A and 1.5 - 6 slices for treatment B.  The average number of 
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slices consumed for each treatment was as follows: control treatment, 4.20 ± 0.53 slices; 
treatment A, 4.16 ± 0.47 slices; and treatment B, 3.85 ± 0.41 slices.  However, there was 
not a significant difference in the amount of kilocalories consumed per treatment, 
eventhough subjects who ingested treatment B consumed, on average, 100 calories less 
cheese pizza (Figure 27).   
 
 
Figure 27 - Kilocalories Consumed Post-Treatment Consumption 
Subjects (n=10) were provided a cheese pizza 180 minutes post-treatment consumption.  The kilocalorie consumption 
per treatment were graphed as the mean ± SEM.   
 
 
Analysis of PYY, GLP-1, Leptin and Ghrelin Plasma Expression 
Blood samples were collected from subjects at 0 (baseline), 30, 90, and 180 
minute time points and were graphed as the change in mean plasma expression from 
baseline.  The change in plasma expression of the following hormones were analyzed: 
GLP-1, ghrelin, leptin and total PYY.  Compared to the control, treatment B 
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demonstrated the greatest GLP-17-36 expression at the 30 and 90 minute timepoints, but 
in neither case were the differences significant.  At the 180 minute timepoint, both 
treatments demonstrated greater GLP-17-36 expression compared to control.  (Figure 
28a).   
The total level of PYY, which includes PYY1-36 and PYY3-36 forms of the 
peptide, were also analyzed.  While none of the total PYY expression differences among 
treatments were significant it is worth noting that at the 30 and 90 minute timepoints 
only the control treatment demonstrated an increase in total PYY concentration, while 
treatment B demonstrated a decrease compared to baseline.  At the 180 minute 
timepoint, treatment A demonstrated the greatest total PYY expression, while treatment 
B demonstrated the smallest decrease (Figure 28b).   
Leptin expression was also analyzed and compared.  There were not any 
significant differences between the three treatments for leptin expression at any of the 
timepoints (Figure 28c).   
Unlike the previously analyzed hormones, ghrelin is considered a hunger 
hormone.  Ghrelin expression among treatments was not significantly different at any 
timepoint, but it should be noted that the control treatment demonstrated the smallest 
ghrelin expression decrease at 30 minutes and the greatest increase at 90, and 180 
minutes compared to baseline and that both treatments demonstrated a smaller level of 
ghrelin expression (Figure 28d). 
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(a) (b) 
  
(c) (d) 
 
Figure 28 – Plasma Hormone Sample Analysis of Treatments. 
The effect of each treatment on the plasma expression of GLP-1, PYY, leptin and ghrelin. For each treatment, change 
from baseline scores were graphed as function of time. Data at each time point is means ± SEM (n = 10). 
 
 
DISCUSSION 
 The goal of phase three was to determine if the emulsion treatments could 
enhance satiety via activation of the ileal brake and to see if there was a correlation with 
the results from phase one.  Due to budgetary, location and time constraints this study 
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was limited to 10 subjects and the length of each study day had to be shortened 
compared to previous studies that often examined the effects for up to eight hours post-
consumption.  Taking those restrictions into consideration, there only appears to be little 
evidence with statistical significance that the emulsion treatments induce satiety, despite 
the fact the emulsions demonstrated a significant increase in PYY and GLP-1 secretion 
in STC-1 cells in phase one.  As demonstrated in phase two, our developed beverage was 
able to mask any sensory, flavor, color, pH and rheological differences of each treatment 
with the only ingredient being different are the emulsions.   Therefore, it is unlikely that 
the treatment differences could have influenced the scorecard ratings or satiety.  There 
were a few instances in the satiety, energy intake and satiety hormone profile tests where 
the results might be worth investigating further to determine if there is a statistically 
significant difference using a larger sample size.  Subjects who consumed Treatment B 
consumed 100 kilocalories less pizza compared to control or treatment A.  Any satiety 
agent that can potentially reduce kilocalorie intake in subsequent meals is an important 
consideration for individuals interested in weight management.  Both treatments A and B 
demonstrated greater expression levels of GLP-1 compared to control.  Analysis and 
interpretation of PYY data is difficult since the analysis kit is unable to distinguish 
between full length PYY and PYY3-36, the truncated form known to specifically exert the 
effects on satiety.  After 30 minutes, treatment B demonstrated the greatest decrease of 
ghrelin expression levels, an effect which persisted throughout the entire 180 minute 
treatment period.  Unlike leptin, GLP-1, and PYY, ghrelin is a hunger hormone 
produced by the stomach and given that treatment B demonstrated the greatest decrease 
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in ghrelin expression could be worth investigating further.  The results showed that the 
expression of leptin significantly decreased was an unanticipated result. The expectation 
was that leptin expression levels would increase following the consumption of the 
treatments.   
 There are several potential factors that could potentially explain the emulsion 
treatments inability to exhibit significant effects on satiety, energy intake and satiety 
hormone circulation.  In the previous studies that examined OlibraTM, the emulsion was 
always consumed in the presence of only yogurt [149-151, 166-171, 173].  Without 
yogurt, the effect on satiety and energy intake was abrogated [171].  Yogurt was 
previously shown to have higher satiety ratings following consumption relative to fruit 
drink or dairy fruit drink, possibly due to higher viscosity [172].  Although, our beverage 
formulated in phase two contained yogurt, the other ingredients such as skim milk 
decreased viscosity, which could have negatively influenced satiety.   One way to 
determine if there was a beverage formulation flaw, would be to follow the same study 
design in phase three and add an additional treatment containing OlibraTM.  OlibraTM, 
emulsion A and emulsion B have a similar fatty acid profile in that they are all 
comprised of over 50% palmitic and oleic acid.  However, the oat oil component was not 
present in emulsion A or B.   The galactolipids present in oat oil have been suggested to 
prevent pancreatic lipase from binding to the emulsion interface in the duodenum and 
thus delay lipid digestion [148].  Therefore adding an oat oil component to emulsions A 
or B is also a future consideration to refining the emulsion formulation.   
 108 
 
Despite the lack of evidence and statistical significance in this pilot study, the 
only way to truly assess the effectiveness of emulsions A & B as satiety inducing agents 
is to recruit more subjects, extend the length of the study day and add OlibraTM as an 
additional treatment.  If the treatments were shown to be effective in appetite 
suppression and reduce energy intake they may provide a cost-effective alternative over 
pharmacological drugs in facilitating weight loss in individuals interested in weight 
management and overall health. 
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CHAPTER V 
SUMMARY AND FUTURE CONSIDERATIONS 
 
SUMMARY OF RESULTS 
Overall Goal 
The goal of this research project was to investigate whether two orally consumed 
emulsions that differed in their palm oil to fish oil ratios, being either 2:1 (A) or 1:1 (B), 
influenced satiety via activation of the ileal brake, a gastric feedback mechanism that 
induces satiety by delaying gastric emptying and inhibiting intestinal motility.  
Biomarkers of the ileal brake and satiety are PYY and GLP-1.  This research project 
consisted of three phases that are summarized below. 
 
Phase One Summary 
Phase one examined whether emulsions A and B stimulated the secretion of PYY 
and GLP-1 from the murine intestinal cell line, STC-1 in vitro.  STC-1 cells secrete PYY 
and GLP-1 upon nutrient stimulation in a manner similar to human L-cells.  In humans, 
PYY and GLP-1 are produced and secreted from the intestinal L-cells of the ileum upon 
nutrient exposure.  Once in circulation, PYY and GLP-1 cross the blood brain barrier 
and bind to their respective receptors in the hypothalamus inducing satiety and reducing 
food intake.  Emulsions A and B served as treatments for the STC-1 cell cultures.  Their 
effect on the secretion of PYY and GLP-1 was analyzed at timepoints of 30, 60, 90 and 
120 minutes.  The results were compared and statistically analyzed using an ANOVA.  
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The results demonstrated that both emulsion treatments promoted GLP-1 and PYY 
secretion from STC-1 cell cultures.  Although, there was not a significant difference 
between emulsion A and emulsion B, indicating that the palm and fish oil ratio were not 
responsible for the difference.  These findings indicated that there may be potential for 
the emulsions to serve as activators of the ileal brake in vivo. 
 
Phase Two Summary 
In phase two, a fruit and dairy beverage was formulated to serve as a vehicle for 
the emulsions in human volunteers.  Each beverage was prepared with either a milkfat 
control, or emulsion A, or emulsion B.  For clarity of terms, each beverage preparation 
was referred to as the control treatment, treatment A and treatment B.  Any subjective 
(sensory) or objective (instrumental analyses) differences in treatments could influence 
the observed results in satiety in human volunteers.  The beverages were formulated with 
the goal of eliminating variations among treatments so that the only differences were in 
reported satiety.  Subjective sensory tests and objective instrumental analyses were 
performed on each treatment and the results were statistically analyzed using an 
ANOVA.  For the subjective sensory tests, triangle tests and acceptance/affective tests 
were administered using untrained subjects.  The objective tests employed laboratory 
instrumentation to analyze and compare the viscosities, pH and Hunter L, a, b color 
values of each treatment.  The results demonstrated that the formulated beverage masked 
any sensory, flavor, color, pH and rheological differences of each treatment with the 
only ingredient being different are the emulsions.     
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Phase Three Summary 
 In phase three, the treatments formulated in phase two were investigated to 
determine if they induced satiety, reduced energy intake, and upregulated the expression 
of satiety biomarkers in human volunteers.  Ten subjects were recruited in a randomized, 
single blind placebo-controlled, crossover study design.  Subjects were instructed to 
complete VAS questionnaires as a baseline (time 0) for the subjective satiety rating prior 
to treatment consumption.  Blood samples were also collected prior to treatment 
consumption as a baseline (time 0).  Over the course of 180 minutes post-treatment 
consumption, VAS questionnaires were completed at 30 minutes intervals.  Additional 
blood samples were collected at 30, 90 and 180 minutes post-treatment consumption.  
Following the 180 minutes of data collection, subjects were provided an eight-slice, 
2000 kilocalorie, cheese pizza satiety lunch for which they were instructed to consume 
until sufficiently satiated.  Upon satiation, the kilocaloric intake from the satiety meal 
was calculated.  The collected blood samples were analyzed for the circulating plasma 
levels of ghrelin, leptin, PYY and GLP-1.  Neither the VAS results, nor biomarker 
results demonstrated significant differences among treatments.  However, although not 
significant, subjects provided treatment B (1:1 palm:fish oil composition), on average 
consumed 100 fewer kilocalories of cheese pizza.   
In order to fully elucidate the role that emulsions play in inferring the activation 
of the ileal brake via upregulation of PYY and GLP-1, a more comprehensive study 
should be considered with the following suggested revisions: larger more representative 
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sample size, more frequent blood collection, have subjects keep record of subsequent 
food intake for up to 24-hours and a satiety lunch that offers a buffet. 
 
FUTURE CONSIDERATIONS 
 
Satiety Study Considerations 
In order to evaluate whether the emulsion beverage treatments promote satiety 
via activation of the ileal brake, a more comprehensive study is necessary which would 
include several refinements of protocol.  The first refinement to the experimental design 
of the study would be to recruit additional subjects.  Statisticians typically recommend 
between 20-30 subjects in order to minimize the effect of outliers and provide adequate 
power to the study.  A much more established method would be to follow Burns et al. 
protocol, whose study involved sixty subjects, with twenty subjects separated into BMI 
categories of normal, overweight and obese.  Each BMI weight category would require 
approximately ten males and ten females and with a more diverse recruitment pool 
[149].  The second refinement would be to expand the recruitment pool, since the satiety 
study in phase three was limited to students at Texas A&M University.  To address this, 
the recruitment pool could be expanded to include any adults, aged 18-60, currently 
residing in the community as per other studies.  The third refinement is to collect 
additional blood samples at the 15, 60, 75, 105, 120, 135, 150 minute timepoints and 
another collection following consumption of the satiety meal to demonstrate the 
anticipated hormone response.  It should be considered however, that additional blood 
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collection intervals may lead to subject discomfort, which could influence 
satiety/appetite.  The fourth refinement would be to include OlibraTM as a treatment to 
serve as a basis for comparison to the results in phase three.  Such a revision could 
clarify if there was a limitation due to beverage or emulsion formulation.  Despite 
conflicting reports, the effects of OlibraTM on satiety are well established [149-151, 166-
171, 173].  The fifth refinement would be to require the subjects to complete records of 
food consumption for the 24 hour period prior to and the 24 hour post-treatment 
consumption.  The sixth refinement would be to provide the subjects an ad libitum lunch 
that consists of a restricted buffet style meal instead of a cheese pizza that has been 
utilized in many studies [149-151, 166-171, 173].  The advantage of an ad libitum buffet 
style lunch is that additional food choices provide subjects access to foods that may suite 
their personal preferences.  As a reminder, the cheese pizza satiety lunch in phase three 
was predetermined by the subjects to be suitable, however a buffet style revision might 
enable the subjects to more accurately mimic normal eating habits and potentially 
provide a more accurate measurement of kilocalorie intake.  An additional refinement to 
consider is the location of the study, specifically the location of the satiety meal.  In the 
study in phase three, subjects consumed their satiety lunch at a large conference table 
located in an open area that prevented privacy.  Although, it can be argued that such a 
setting is more appropriate in mimicking real world eating situations.   
Despite the lack of statistical significance in the satiety study, a more 
comprehensive way to assess the satiety effects of both emulsions is to implement the 
refinements to the study design.  If either of the emulsions are demonstrated to promote 
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satiety, they may provide cost-effective alternative over pharmacological drugs in 
facilitating weight loss in subjects who desire to improve their weight and overall health. 
 
Beverage Formulation and Product Development Considerations 
There is a possibility that the emulsion delivery method and/or formulations were 
a factor in the phase three results.  This section will address the considerations in the 
beverage formulated in phase two.  In order to fully characterize the treatment sensory 
parameters, descriptive analysis could be administered using trained panelists.  Unlike 
the affective and triangle tests where untrained panelists provided quantitative 
assessments of quality, descriptive analysis provides qualitative descriptions of the 
sensory attributes of a food.  Such a test would further clarify the beverage sensory 
parameters to aid in product development. 
While the beverage was successful in masking the flavor of the emulsions, 
several formulation adjustments could be considered for future studies.  The critical 
beverage ingredient is the fat free yogurt since it was combined with OlibraTM in all 
previous studies [149-151].  Most importantly, OlibraTM was shown to be ineffective in 
inducing satiety without yogurt [171].  Consumption of yogurt alone was demonstrated 
to promote satiety compared to consumption of a fruit drink or dairy fruit smoothie, 
possibly due to higher viscosity [172].  The skim milk dispersed the ingredients and 
contributed to mouthfeel, but lowered the viscosity, which may have decreased satiety.  
Although, the Jell-O pudding component possessed ingredients that function as 
emulsifiers and thickening agents, the final quantity of said ingredients in the treatments 
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was unlikely to have an effect on viscosity.  To further increase beverage viscosity, a 
thickening agent such as low-methoxy pectin may be included in the formulation.  
Unlike high methoxy pectin, low-methoxy pectin does not require significant amounts of 
sugar to gel properly, although the addition of calcium may be necessary.  As 
formulated, the beverage pH was measured at 4.75, which is within the pH tolerance 
range (2.5-5.5) for pectin gelation.  The cinnamon, vanilla extract contributed to flavor, 
while the chocolate syrup contributed to the flavor, color and texture.  Chocolate syrup 
provided the treatments their light brown color.  It is unlikely that the chocolate syrup, 
cinnamon or vanilla extract negatively impacted satiety.   
While shelf life is a minor factor in evaluating the treatments effects on satiety, it 
is a significant factor when considering commercial viability.  As such, improving 
beverage shelf life should be considered a priority.  One modification in the beverage 
formulation that may improve the shelf life, would be the removal of the fruit 
component.  While fresh strawberries and bananas provided flavor, they undergo 
spoilage more rapidly than the other ingredients.   The removal of the milk component is 
a consideration, since it may also contribute to rapid spoilage.  Potential fat free 
replacements include almond milk, coconut milk, soy milk, rice milk or hemp milk.    
Pasteurization and the addition of antimicrobial agents such as sodium benzoate are also 
considerations that may prolong the shelf life.  Any reformulation of the beverage 
treatments would require repeating the subjective and objective tests from phase two.   
 
 
 116 
 
Emulsion Delivery and Formulation Considerations 
There is a possibility that the emulsion delivery method and/or formulations were 
a factor in the phase three results.  If the beverage formulated in phase two was 
determined to be ineffective as an emulsion delivery system, emulsion encapsulation or 
emulsion component reformulation may be considered for refinements in experimental 
design.  Emulsion encapsulation by alginate beads is a consideration, since it has been 
shown to delay lipid digestion, potentially increasing lipid exposure to the ileum [194, 
195].  Reformulation factors which address specific components of the emulsion, 
including emulsifier charge or refinement of the oil phase, are discussed below. 
It was demonstrated that emulsifiers with charged functional groups promote a 
high-surfactant-to-bile ratio, which can inhibit lipolysis by preventing mixed micelle 
formation [196].  Inhibition of lipolysis increases the emulsion intestinal transit time and 
therefore increases the possibility of free fatty acids, liberated from the oil component of 
the emulsions, reaching the ileum intact.  Both emulsions examined in the satiety study 
were prepared by Omega Pure with diacetyl tartaric acid ester of mono-diglycerides 
(DATEM) serving as the primary emulsifier.  Aside from a single carboxylic acid, 
DATEM does not possess any charged functional groups which may have affected 
emulsion stability.  However, since casein served as the secondary emulsifier to provide 
an additional layer of stability, such an effect was likely minimized, but is still a 
consideration. 
 Another formulation consideration would be to incorporate oat oil into the 
emulsion formulation since it is a critical component of OlibraTM.  Oat oil contains 
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galactolipids, which due to their bulk size prevent pancreatic lipases from binding to the 
emulsion interface in the duodenum, delaying lipid digestion [148].  Therefore, 
reformulating emulsions A and B to include an oat oil component is a consideration.   
 In summary, factors such as encapsulation, emulsifier charge and oil composition 
are all considerations in reformulating the emulsion and/or delivery method to promote 
delayed lipid digestion that may increase lipid exposure to the ileum. 
 
Summary 
 The experimental results in phase three did not support the hypothesis that 
emulsions induce satiety through inferred activation the ileal brake in human subjects.  
However, the study was limited in the number of subjects, area of recruitment, number 
of blood collection intervals and satiety meal offering.  As such, experimental design 
refinements could be implemented into future satiety studies that would further clarify if 
such was the case.  Changes to implement in the satiety study include, the recruitment of 
additional subjects, offering a greater variety in food selection for the satiety lunch, 
expanding the recruitment pool and the collection of blood samples at additional 
timepoints.  Beverage formulation considerations include subjective tests with trained 
panelists, increasing beverage viscosity and prolonging the shelf life.  Emulsion 
formulation may be enhanced by the addition of an oat oil fraction, altering the choice of 
emulsifier or encapsulation of the emulsions to serve as an alternative vehicle for 
delivery to the ileum.   
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